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An estimated 69 000 people die each 
year from opioid overdose, which is 
easily treatable with naloxone and basic 
resuscitation techniques, a treatment that 
is usually only available in ambulances and 
hospital settings. Most opioid overdoses 
are witnessed, often by someone known 
to the person who has overdosed, such 
as a friend, family member or professional 
whose work brings them into contact with 
people at risk of overdose. This guideline 
makes specific recommendations for 
health services to work with such lay 
persons who are likely to witness an opioid 
overdose, to enable them to treat opioid 
overdose in an emergency situation and 
prevent further opioid overdose deaths. 
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GLOSSARY OF TERMS USED IN THESE GUIDELINES
abstinence
Refraining from alcohol or drug use. The term “abstinence” should not be confused with the term “abstinence 
syndrome”, which refers to a withdrawal syndrome.
agonist 
A substance that acts at a neuronal receptor to produce effects similar to those of a reference drug; for example, 
heroin is a morphine-like agonist at opioid receptors.
antagonist  
A substance that counteracts the effects of another agent. Pharmacologically, an antagonist interacts with 
a receptor to inhibit the action of agents (agonists) that produce specific physiological or behavioural effects 
mediated by that receptor.
delirium 
An acute organic cerebral syndrome characterized by concurrent disturbances of consciousness, attention, 
perception, orientation, thinking, memory, psychomotor behaviour, emotion, and the sleep-wake cycle. Duration 
is variable from a few hours to a few weeks and the degree of severity ranges from mild to very severe. An 
alcohol-induced withdrawal syndrome with delirium is known as delirium tremens.
dependence 
A cluster of physiological, behavioural and cognitive phenomena in which the use of a substance or a class of 
substances takes on a much higher priority for a given individual than other behaviours that once had greater 
value. A central descriptive characteristic of the dependence syndrome is the desire (often strong, sometimes 
overpowering) to take psychoactive drugs (which may or may not have been medically prescribed), alcohol or 
tobacco.
depressant 
Any agent that suppresses, inhibits, or decreases some aspects of central nervous system (CNS) activity. The 
main classes of CNS depressants are the sedatives/hypnotics (alcohol, barbiturates, benzodiazepines), opioids, 
and neuroleptics. Anticonvulsants are sometimes included in the depressant group because of their inhibitory 
action on abnormal neural activity. Disorders related to depressant use are classified as psychoactive-substance 
use disorders in ICD-10 in categories F10 (for alcohol), F11 (for opioids), and F13 (for sedatives or hypnotics). 
See also: opioid; sedative/hypnotic.
detoxification 
Also referred to as managed withdrawal or supported withdrawal, detoxification describes supported cessation 
of a psychoactive substance. 
illicit drug 
A psychoactive substance, the production, sale, or use of which is prohibited. Strictly speaking, it is not the 
drug that is illicit, but its production, sale, or use in particular circumstances in a given jurisdiction. “Illicit drug 
market”, a more exact term, refers to the production, distribution and sale of any drug outside legally-sanctioned 
channels.
intoxication 
A condition that follows the administration or consumption of a psychoactive substance causing disturbances in 
the level of consciousness, cognition, perception, judgement, affect or behaviour, or other psychophysiological 
functions and responses. 
v
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multiple drug use  
The use of more than one drug or type of drug by an individual, at the same time or sequentially, usually with 
the intention of enhancing, potentiating or counteracting the effects of another drug. The term is also used 
more loosely to include the unconnected use of two or more drugs by the same person. 
naloxone 
An opioid-receptor blocker that antagonizes the actions of opioid drugs. It reverses the features of opiate 
intoxication and is prescribed for the treatment of overdose with this group of drugs. See also: antagonist.
opiate 
One of a group of alkaloids derived from the opium poppy (Papaver somniferum) with the ability to induce 
analgesia, euphoria and, in higher doses, stupor, coma and respiratory depression. The term opiate excludes 
synthetic opioids. See also: opioid.
opioid 
A generic term applied to alkaloids from the opium poppy (Papaver somniferum), their synthetic analogues and 
compounds synthesized in the body, which interact with the same specific receptors in the brain, have the 
capacity to relieve pain and produce a sense of well-being (euphoria). The opium alkaloids and their synthetic 
analogues also cause stupor, coma and respiratory depression in high doses.
opioid maintenance treatment 
Also referred to as opioid agonist maintenance treatment or opioid substitution treatment. Examples of opioid 
maintenance therapies are methadone and buprenorphine maintenance treatment. Maintenance treatment 
can last from several months to more than 20 years, and is often accompanied by other treatment (such as 
psychosocial treatment). 
overdose 
The use of any drug in such an amount that acute adverse physical or mental effects are produced. Deliberate 
overdose is a common means of suicide and attempted suicide. In absolute numbers, overdoses of licit drugs 
are usually more common than those of illicit drugs. Overdose may produce transient or lasting effects, or death. 
The lethal dose of a particular drug varies with the individual and with circumstances. See also: intoxication; 
poisoning.
poisoning, alcohol or drug 
A state of major disturbance of consciousness level, vital functions and behaviour following the administration 
in excessive dosage (deliberately or accidentally) of a psychoactive substance. In the field of toxicology, the 
term poisoning is used more broadly to denote a state resulting from the administration of excessive amounts 
of any pharmacological agent, psychoactive or not. See also: overdose; intoxication.
polydrug use/abuse  
See multiple drug use.
psychosocial intervention 
Any non-pharmacological intervention carried out in a therapeutic context at an individual, family or group level. 
Psychosocial interventions range from structured, professionally-administered psychological interventions 
(such as cognitive behaviour therapy or insight-oriented psychotherapy) to non-professional psychological and 
social interventions (such as self-help groups and non-pharmacological interventions from traditional healers, 
accommodation, financial support, legal support, employment assistance, information and outreach). 
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rebound toxicity 
The re-emergence of respiratory depression and other features of opioid overdose following the temporary 
reversal of opioid overdose symptoms with an opioid antagonist such as naloxone.
relapse 
A return to drinking or other drug use after a period of abstinence, often accompanied by reinstatement of 
dependence symptoms. Some distinguish between relapse and lapse (“slip”), with the latter denoting an 
isolated occasion of alcohol or drug use.
 
sedative/hypnotics 
Central nervous system depressants that relieve anxiety and induce calmness and sleep. Several such drugs 
also induce amnesia and muscle relaxation and/or have anticonvulsant properties. Major classes of sedatives/
hypnotics include alcohol, the benzodiazepines and the barbiturates. 
substance use disorders 
This concept includes both the dependence syndrome and the harmful use of psychoactive substances such 
as alcohol, cannabis, amphetamine-type stimulants (ATS), cocaine, opioids and benzodiazepines.
tolerance 
A decrease in response to a drug dose that occurs with continued use. Increased doses of alcohol or other drugs 
are required to achieve the effects originally produced by lower doses. Both physiological and psychosocial 
factors may contribute to the development of tolerance, which may be physical, behavioural or psychological. 
withdrawal syndrome 
Also known as abstinence syndrome, withdrawal reaction, or withdrawal state. A group of symptoms of variable 
clustering and degree of severity that occur on cessation or reduction of the use of a psychoactive substance 
that has been taken repeatedly, usually for a prolonged period or in high doses (ICD-10 code F1x.3). The onset 
and course of a withdrawal syndrome are time limited and relate to the type of substance and dose being 
taken immediately before cessation or reduction of use. Typically, the features of a withdrawal syndrome are 
the opposite of acute intoxication.
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ABC airway, breathing, and circulation
aRR adjusted relative risk
AIDS acquired immunodeficiency syndrome
AMA against medical advice
ART anti-retroviral treatment
BBV blood borne virus
BLS basic life support
CI confidence interval
CND Commission on Narcotic Drugs
COCPR chest compression only cardiopulmonary resuscitation
CNS central nervous system
CPR cardiopulmonary resuscitation
CPS controlled prospective study
ECOSOC United Nations Economic and Social Council
EMS emergency medical services
GCS Glascow Coma Scale
GDG guideline development group
GRADE Grading of Recommendations Assessment, Development and Evaluation 
HCV hepatitis C virus
HIV human immunodeficiency virus
ICD-10 International Classification of Diseases, 10th edition
IM intramuscular
IN intranasal
IQR inter-quartile range
IV intravenous
OD overdose
OR odds ratio
PICO population, intervention, comparison, outcome
PWID people who inject drugs
PWUD people who use drugs
RevMAN Review Manager
RR relative risk or risk ratio
RCT randomized controlled trial
SC subcutaneous
SMD standardized mean difference
TB tuberculosis
UNODC United Nations Office on Drugs and Crime
WHO World Health Organization
OR odds ratio
ACRONYMS & ABBREVIATIONS
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EXECUTIVE SUMMARY 
Opioids are potent respiratory depressants, and overdose is a leading cause of death among people who use 
them. Worldwide, an estimated 69 000 people die from opioid overdose each year. The number of opioid 
overdoses has risen in recent years, in part due to the increased use of opioids in the management of chronic 
pain. In 2010, an estimated 16 651 people died from an overdose of prescription opioids in the United States 
of America alone. 
Opioid overdose is treatable with naloxone, an opioid antagonist which rapidly reverses the effects of opioids. 
Death does not usually occur immediately, and in the majority of cases, overdoses are witnessed by a family 
member, peer or someone whose work brings them into contact with people who use opioids. Increased access 
to naloxone for people likely to witness an overdose could significantly reduce the high numbers of opioid 
overdose deaths. In recent years, a number of programmes around the world have shown that it is feasible 
to provide naloxone to people likely to witness an opioid overdose, in combination with training on the use of 
naloxone and the resuscitation of people experiencing opioid overdose, prompting calls for the widespread 
adoption of this approach. In 2012, the United Nations Economic and Social Council (ECOSOC) called upon 
the World Health Organization (WHO), in collaboration with the United Nations Office on Drugs and Crime 
(UNODC) to provide advice and guidance, based on scientific evidence, on preventing mortality from drug 
overdose, in particular opioid overdose.
While community management of opioid overdose with naloxone is expected to reduce the proportion of 
witnessed opioid overdoses which result in death, it does not address the underlying causes of opioid overdose. 
To further reduce the number of deaths due to opioid overdose other measures should be considered, such as: 
 o monitoring opioid prescribing practices;
 o curbing innapropriate opioid prescribing;
 o curbing inappropriate over-the-counter sales of opioids; 
 o increasing the rate of treatment of opioid dependence, including for those dependent on prescription 
opioids.   
Objectives of the guidelines
These guidelines aim to reduce the number of deaths from opioid overdose by providing evidence-based 
recommendations on the availability of naloxone for people likely to witness an opioid overdose along with 
advice on the resuscitation and post-resuscitation care of opioid overdose in the community. Specifically, these 
guidelines seek to:
 o increase the availability of naloxone to people likely to witness an opioid overdose in the pre-hospital setting;
 o increase the preparedness of people likely to witness an opioid overdose to respond safely and effectively 
by carrying naloxone and being trained in the management of opioid overdose; 
 o increase the rate of effective resuscitation and post-resuscitation care by persons witnessing an opioid 
overdose.
The guidelines aim to meet these objectives by:
 o informing health policy-makers of the benefits of increased availability and use of naloxone and effective 
resuscitation in the pre-hospital setting; 
 o informing programme managers of the benefits of developing programmes to equip people likely to witness 
an opioid overdose with naloxone and to train them in managing an opioid overdose; 
 o informing medical practitioners of the benefits of prescribing naloxone to people at risk of opioid overdose 
and providing advice on the management of opioid overdose. 
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How these guidelines were developed
Development of these guidelines began in October 2013 with the identification of the key issues for which 
advice was needed. The WHO steering group and Guideline Development Group (GDG) were established 
and appropriate clinical questions were formulated. These were then set in the PICO format (population, 
intervention, comparator, outcome) and systematic reviews were conducted for each PICO question. The 
quality of the evidence was then assessed according to GRADE criteria. A narrative evidence synthesis was 
also provided. A GDG meeting was held in Geneva (19-20 February 2014). Evidence of values and preferences, 
cost-effectiveness, feasibility and resource use was presented along with the evidence of benefits and harms 
and the GDG formulated recommendations taking all these domains into consideration. 
The strength of the recommendation was set as either:
‘strong’: meaning that the GDG was confident that the evidence of effect, combined with 
certainty about the values, preferences, benefits and feasibility, made this a recommendation 
that should be applied in most circumstances and settings;
or
‘conditional’: meaning that there was less certainty about the evidence of effect and values, 
preferences, benefits and feasibility of this recommendation. Thus there may be circumstances 
or settings in which the recommendation does not apply. 
x
TABLE 1. SUMMARY OF THE RECOMMENDATIONS
No. Recommendation
Strength of 
recommendation
Quality of 
evidence
 People likely to witness an opioid overdose should have access 
to naloxone and be instructed in its administration to enable them 
to use it for the emergency management of suspected opioid 
overdose. 
Strong Very low
2 Naloxone is effective when delivered by intravenous, 
intramuscular, subcutaneous and intranasal routes of 
administration. Persons using naloxone should select a route of 
administration based on the formulation available, their skills in 
administration, the setting and local context.
Conditional Very low
3 In suspected opioid overdose, first responders should focus on 
airway management, assisting ventilation and administering 
naloxone.
Strong Very low
4 After successful resuscitation following the administration 
of naloxone, the level of consciousness and breathing of the 
affected person should be closely observed until full recovery has 
been achieved.
Strong Very low
INTRODUCTION 
Opioids are potent respiratory depressants, and overdose is a leading cause of death among people who use 
them. Worldwide, an estimated 69 000 people die from opioid overdose each year (1). Among people who 
inject drugs, opioid overdose is the second most common cause of mortality after HIV/AIDS (2). A recent rise 
in opioid-overdose deaths in a number of countries is associated with an increase in the prescribing of opioids 
for chronic pain (3–5). In 2010, an estimated 16 651 people died from an overdose of prescription opioids in the 
United States of America alone (6). 
Opioid overdose
Opioids depress the respiratory drive and overdose is characterised by apnoea, myosis and stupor. A severely 
reduced respiration rate results in hypoxaemia, leading to cerebral hypoxia and impaired consciousness. 
Cardiac arrest is a late complication of opioid overdose and secondary to respiratory arrest and hypoventilation. 
Prolonged cerebral hypoxia is the mechanism for brain injury and death in opioid overdose, resulting from 
apnoea or cardiac dysrhythmias and cardiac arrest.
Opioids act at μ, κ and δ-opioid receptors, which are widely distributed throughout the body. Endogenous 
opioids act tonically on brain-stem-located opioid receptors to modulate respiration in response to hypoxia and 
hypercapnea (7). These centres are in turn modulated by connections to other structures in the central nervous 
system (CNS) including the motor cortex, the cerebellum and limbic centres. Administered opioids depress all 
components of the respiratory drive (the rate and depth of breathing). An effect most pronounced in individuals 
with chronic cardio-pulmonary and renal disease, whose respiratory responses are diminished. In addition to 
reducing respiratory drive, opioids reduce upper-airway tone and chest-wall rigidity.
Preventing opioid overdose
While community management of opioid overdose with naloxone is expected to reduce the proportion of 
witnessed opioid overdoses which result in death, it does not address the underlying causes of opioid overdose. 
To further reduce the number of deaths due to opioid overdose other measures should be considered (8), such 
as: 
 o monitoring opioid prescribing practices;
 o curbing innapropriate opioid prescribing;
 o curbing inappropriate over-the-counter sales of opioids; 
 o increasing the rate of treatment of opioid dependence, including for those dependent on prescription 
opioids.   
Who is at risk of an opioid overdose 
People dependent on opioids are the group most likely to experience an overdose. The incidence of fatal opioid 
overdose among opioid-dependent individuals is estimated at 0.65 per 100 person years (8). Non-fatal opioid 
overdoses are several times more common than fatal ones (9).  
A number of risk factors lead to increased likelihood of a fatal opioid overdose. Injecting opioid users are at 
elevated risk, particularly when first using injection as a route of administration (10–12).
A reduction in tolerance, seen when opioid use is restarted after a period of abstinence, markedly increases 
the risk of an opioid overdose (13, 14). This commonly occurs during the first few weeks after release from 
incarceration (15–17), after discharge from inpatient or residential detoxification, or cessation of drug dependence 
treatment (including treatment with the opioid antagonist naltrexone) (18–21). 
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People who inject drugs and have HIV infection have an increased risk of overdose but it is unclear if the 
mechanism is direct or relates to a combination of biological, risk-behavioural and structural factors (26). Liver 
disease may also impair hepatic opioid metabolism (27) and therefore contribute to lowering overdose thresholds 
among individuals with chronic viral hepatitis, particularly long-standing hepatitis C viral infection (28).
Although people taking prescribed opioids are at lower risk of overdose than people using unprescribed opioids, 
the high number of people receiving prescribed opioids in many  countries mean that they constitute a significant 
proportion of opioid overdose deaths, if not the majority. Risk factors for overdose in people taking prescribed 
opioids include higher prescribed dosage, male gender, older age (29, 30), multiple prescriptions (including 
benzodiazepines) (31), mental health disorders and lower socioeconomic status (32–34). The risk of overdose is 
significantly higher where the prescribed dose is 100 mg morphine equivalents daily or greater (29).
Who is likely to witness an opioid overdose 
Most opioid overdoses occur in private homes (35), and most of these are witnessed (36–38). Close friends, a 
partner or family members are most likely to witness an opioid overdose (39, 40).
The other key group of individuals likely to witness overdoses are people working with people who use drugs. 
They include trained health professionals and first responders, such as ambulance, police, fire and drug-
treatment workers as well as outreach workers.
Management of opioid overdose 
Death in opioid-overdose can be averted by emergency basic life support resuscitation and/or the timely 
administration of an opioid antagonist such as naloxone.
Naloxone (n-allylnoroxymorphone) has been used in opioid overdose management for over 40 years, with 
minimal adverse effects beyond the induction of opioid withdrawal symptoms (42). It is a semisynthetic 
competitive opioid antagonist with a high affinity for the μ opioid receptor. It rapidly displaces most other 
opioids from opioid receptors, and if given soon enough will reverse all clinical signs of opioid overdose. It can 
be administered by a variety of routes including intravenously (IV), intramuscularly (IM), subcutaneously (SC) 
and intranasally (IN). It carries no potential for abuse, although high doses may lead to the development of 
opioid withdrawal symptoms such as vomiting, muscle cramps and agitation.
Access to naloxone
Access to naloxone is generally limited to health professionals, and in many countries there is limited availability 
of naloxone even in medical settings, including ambulances. 
Naloxone is a prescription medicine in almost all countries, and while it is not usually prescribed to people 
likely to witness an opioid overdose, at least one country has made naloxone available in pharmacies without 
prescription.
Why these guidelines were developed
In recent years, several countries in different regions have started distributing naloxone to people likely to 
witness an opioid overdose, initially in pilot programmes, but now also in some cases state or national policy, 
demonstrating the feasibility of this approach and prompting calls for widespread adoption of this approach (43).
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In 2012, the United Nations Economic and Social Council (ECOSOC) called upon the World Health Organization 
(WHO), in collaboration with the United Nations Office on Drugs and Crime (UNODC), to provide evidence-
based guidance on preventing mortality from drug overdose, in particular opioid overdose (44).
Existing relevant guidelines on related problems and disorders
The table below lists existing WHO guidelines containing recommendations on the use of naloxone for the 
management of opioid overdose. They recommend using a dose of 0.4 mg naloxone and repeating the dose 
if necessary, and suggest monitoring the person for four hours after resuscitation. These guidelines also state 
that it is not necessary to retain people against their will during this period, and that long-acting-opioid overdose 
should be managed in hospital with assisted ventilation and/or naloxone infusion. 
Naloxone is already recommended for use by trained health care providers managing opioid overdose and 
is included in the WHO Model Lists of Essential Medicines. However, there is currently no guidance on use 
of naloxone by those who witness an overdose in a non-hospital, community setting. The current guidelines 
were developed to provide advice on who should be provided with naloxone, on dosage, administration and 
accompanying actions, particularly cardio-respiratory resuscitation.
TABLE 2. EXISTING RELEVANT WHO GUIDELINES RELATED TO OPIOID OVERDOSE
WHO guidelines Recommendations
Guidelines for the Psychosocially Assisted Pharma-
cological Treatment of Opioid Dependence (2009)
http://www.who.int/substance_abuse/publications/
opioid_dependence_guidelines.pdf  
Contains recommendations on the treatment of opioid 
dependence, including opioid overdose, but does 
not address the issue of non-medical availability of 
naloxone. 
MhGAP – Intervention Guide (WHO, 2010)
http://www.who.int/mental_health/evidence/mhGAP_
intervention_guide/en/ index.html
Contains recommendations on management of opioid 
overdose and on how to respond to drug-use disorders 
in general (i.e. after the overdose has resolved).
The ASSIST linked brief intervention for hazardous or 
harmful substance use  (WHO, 2010)
http://whqlibdoc.who.int/
publications/2010/9789241599399_eng.pdf
Contains recommendations on how to talk to people 
about their substance use.
IMAI District Clinical Manual: Hospital Care for 
adolescents and Adults (WHO, 2011)
http://www.who.int/hiv/pub/imai/imai2011/en/
Contains recommendations on the management of 
opioid overdose in the emergency-department setting. 
Who should use these guidelines
These guidelines are relevent to health policy-makers and services that care for people at risk of opioid overdose 
and people likely to witness an opioid overdose in the community setting.
People likely to witness an opioid overdose in the community setting include: 
 o people at risk of an opioid overdose, their friends and families; 
 o people whose work brings them into contact with people who overdose (health care workers, police, 
emergency service workers, people providing accommodation to people who use drugs, peer education 
and outreach workers).
The following are examples of health service which could provide people likely to witness an opioid overdose 
with access to naloxone and training in its use:
 o drug treatment services
 o pain clinics prescribing opioids
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 o HIV treatment services
 o hospital emergency departments
 o emergency care services.
Objectives and scope of these guidelines
The objective of these guidelines is to reduce the mortality and morbidity of opioid overdose by improving the 
pre-hospital management of opioid overdose. Specifically, the guidelines seek to:
 o increase the availability of naloxone to people likely to witness an opioid overdose in the pre-hospital setting;
 o increase the preparedness of people likely to witness an opioid overdose to respond safely and effectively 
by carrying naloxone and being trained in the management of opioid overdose; 
 o increase the rate of effective resuscitation and post-resuscitation care by persons witnessing an opioid 
overdose.
The guidelines aim to meet these objectives by:
 o informing health policy-makers of the benefits of increased availability and use of naloxone and effective 
resuscitation in the pre-hospital setting; 
 o informing programme managers of the benefits of developing programmes to equip people likely to witness 
an opioid overdose with naloxone and to train them in managing an opioid overdose; 
 o informing medical practitioners of the benefits of prescribing naloxone to people at risk of opioid overdose 
and providing advice on the management of opioid overdose. 
Individuals and partners involved in development of the guidelines
Members of the project’s WHO Steering Group were drawn from Management of Substance Abuse, HIV, 
Essential Medicines and Health Products, Injury and Violence Prevention, Global TB Programme, and Service 
Delivery and Safety teams (see Annex 7 for details).
The project’s Guideline Development Group (GDG) was made up of content experts from all WHO regions, five 
of whom were female. A full list of members, their affiliations, expertise and countries is provided in Annex 7.
Observers representing people at risk of opioid overdose and other stakeholder groups attended the GDG 
meeting in Geneva in February 2014, provided comments and technical information but did not participate in 
formulation of the recommendations. A full list of observers who attended the meeting and their affiliations is 
available in ‘Acknowledgements’ on page 5. 
The GDG was supported by several consultants, three who performed the systematic reviews and provided 
all background documentation, and a fourth who advised on WHO guideline development methodology. A 
GRADE methodologist reviewed the findings of the systematic review and developed the GRADE evidence 
profile (see Annex 8 for details).
The External Review Group, whose members were drawn from people who may be affected by the guidance 
and people with content expertise, assessed all the evidence profiles and draft recommendations. The 
systematic reviewers and GDG considered their comments when finalizing the recommendations. A full list 
of external reviewers, their affiliations, countries, and expertise is provided in Annex 7. 
Management of conflicts of interest
All GDG members, external reviewers and consultants completed the WHO Declaration of Interest forms. 
Several GDG members declared academic and financial interests. These were then reviewed by the secretariat 
for potential conflicts of interest. Where conflicts of interest were assessed as potentially serious, they were 
referred to the WHO legal department (see summary in Annex 8). The declared interest of Bob Balster (chair) 
was determined not to represent a conflict for these guidelines. Two GDG members were assessed to have a 
serious conflict of interest. Raka Jain’s conflict was assessed as serious as she had received funding from Rusan 
Pharmaceuticals, a manufacturer of naloxone, although it was for work on an unrelated product. John Strang’s 
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conflict was considered serious because his organization had received funding from Martindale, a manufacturer 
of naloxone, even though the funding was for work on an unrelated product, and because of his current work 
on a non-injectable formulation of naloxone. Both were excluded from participation in discussions and decisions 
relating to the use and availability of naloxone. The remaining conflicts of interest were not considered serious 
and thus all other GDG members were able to participate in all decisions.  
How the guidelines were developed 
These guidelines were developed in accordance with the WHO Handbook for Guideline Development (45), and 
the process was overseen by the WHO Guidelines Review Committee. Development of the guidelines began 
in October 2013 with the establishment of the WHO Steering Group and the Guideline Development Group 
(GDG) which identified the key questions on which advice was needed. These questions were then formulated 
in PICO format (population, intervention, comparator, outcome). The GDG selected a list of outcomes for each 
PICO question and then ranked these by importance on a scale from 1 to 9. A ranking of 7–9 was considered 
“critical”, 4–6 “important” and 1–3 “not important”. Only critical and important outcomes were considered. 
Systematic evidence search and retrieval
The seven key questions governed the search strategy for the systematic reviews. There was considerable 
overlap in the areas to be searched, so for efficiency the strategy for searching the medical-literature databases 
for each of the reviews was combined and the inclusion and exclusion criteria were applied separately by the 
persons reviewing the results of the database search (see Annex 1 for details of the search strategy).
To obtain reliable estimates of effect for the different PICO questions, it was agreed that eligible studies be 
limited to randomized controlled trials (RCTs) or controlled prospective studies published in peer-reviewed 
journals, or presented as abstracts at scientific conferences, between 1 January 1966 and 1 January 2014. The 
search identified 5597 articles. These were screened by a single researcher, yielding 512 potentially relevant 
studies.  Further screening by two researchers independently (disagreement resolved by discussion) reduced 
these to 29 relevant studies. Three researchers, including a GRADE methodologist, independently screened 
and agreed on the final three included studies. 
Data analysis was conducted using Review Manager (RevMan) Version 5.2 (The Nordic Cochrane Centre, 
Copenhagen) and GRADEprofiler (GRADEpro) version 3.6 (the GRADE working group). Where there was no 
effect size or studies could not be assessed using GRADEpro a narrative summary of the evidence was provided 
(see summaries in Annexes 2, 3, 4, and 5).
Evidence to recommendations
FIGURE 1. STUDY SELECTION FLOW DIAGRAM
REFERENCES
5594
5082 excluded by 
initial reviewer
POTENTIALLY 
RELEVANT 
ABSTRACTS 
IDENTIFIED
512
483 abstracts 
excluded by 
2 reviewers by 
consensus
FULL TEXT 
ARTICLES 
ASSESSED FOR 
ELIGIBILITY
29
26 studies excluded 
by 3 reviewers by 
consensus
STUDIES 
INCLUDED
3
PICO 1 – no studies
PICO 2 – 2 studies
PICO 3 – no studies
PICO 4 – no studies
PICO 5 – no studies
PICO 6 – 1 study
PICO 7 – no studies
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The quality of the evidence retrieved was assessed using GRADE methodology (46–47). GRADE evidence profiles 
were developed for each key question, summarizing the quality of the evidence, a narrative assessment of 
benefits versus risks and harms, the estimated values and preferences of those who might be affected by the 
guidelines, and the costs, resource utilization and feasibility of the proposed interventions. Where necessary, 
these narrative descriptions also referred to other relevant evidence, not included in the systematic reviews, 
including one interrupted time-series analysis and 20 case series of programmes that had distributed naloxone 
(relevant to key questions 1–3), and five case series of opioid overdose recovery after naloxone (relevant to 
key question 5). The characteristics of these studies and relevant outcomes are presented in Annexes 2–5.
An online survey was conducted by WHO to assess the values and preferences of those affected by the 
guidelines. This was completed by 661 respondents from 45 countries, including people at risk of opioid 
overdose, people with family members or friends who have overdosed or are at risk of opioid overdose, and 
people whose work brings them into contact with people who have experienced overdose and people at risk 
of overdose. A separate survey of 32 key informants was conducted by a consultant to the Department of HIV/
AIDS, as part of a survey on HIV prevention, testing, treatment, harm reduction and community distribution of 
naloxone (see Annex 6 for a detailed extract from the survey).
With the exception of the values-and-preferences survey and key-informant results, the GRADE profiles were 
circulated for external review prior to the face-to-face meeting of the GDG.
The guideline development meeting, held in Geneva (19–20 February 2014), was attended by GDG members 
and observers from organizations working with or representing people who use drugs, relevant professional 
societies, concerned government health agencies, intergovernmental organizations and WHO collaborating 
centres. Materials presented included GRADE evidence profiles, evidence summaries and systematic reviews, 
along with background documentation and findings from the values-and-preferences survey and key-informant 
interviews. 
A GRADE decision table was used to guide the determination of the strength of each recommendation (strong 
or conditional), based on the quality of the evidence, whether benefits outweighed harms, whether values and 
preferences of guideline end-users favoured the recommendation, and whether or not the recommendation 
was feasible and cost-effective (see Annexes 2-5 for the decision tables).
The strength of each recommendation was set as either:
‘strong’: meaning that the GDG was confident that the evidence of effect, combined with 
certainty about the values, preferences, benefits and feasibility, made this a recommendation 
that should be applied in most circumstances and settings;
or
‘conditional’: meaning that there was less certainty about the evidence of effect and values, 
preferences, benefits and feasibility of this recommendation. Thus there may be circumstances 
or settings in which the recommendation does not apply. 
At the beginning of the meeting, the GDG agreed that decisions on the strength and wording of recommendations 
would preferably be reached by consensus – defined as a state where all members of the GDG agree with 
the wording of recommendations and accompanying comments. It was further agreed that when unanimous 
agreement could not be achieved, an open vote would be held and decisions carried by a simple majority 
(more than 50%). In the meeting, the wording of all recommendations was agreed by consensus, and voting 
was not required.  
While discussing the recommendations, the GDG recommended that the scope of the guidelines be limited 
to pre-hospital care, enabling the guideline to be better targeted to opioid overdose in the community setting. 
This meant that several of the questions (key question 6 on use of naltrexone and naloxone infusion and key 
question 7 on the use of flumazenil in the management of mixed opioid and sedative overdose) were no longer 
within the scope of the guideline and were therefore not discussed further at the meeting.
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Peer review process
After the meeting, the draft recommendations and background systematic reviews were circulated to a group 
of external reviewers (see Annex 7 for details). Revision of the draft recommendations and remarks was made 
if reviewers identified an issue that had not been considered at the guidelines meeting or proposed changes 
which improved the clarity of the text without changing the meaning. The revised recommendations were then 
circulated among the GDG members and proposed changes were accepted if agreed upon by the entire group.
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RECOMMENDATIONS  
Key question 1 – naloxone distribution (see Annex 2 for details)
Background
Naloxone is a semisynthetic competitive opioid antagonist with highest affinity for the μ-receptor, though it 
also acts at κ and δ-opioid receptors. It rapidly reverses all clinical signs of opioid overdose when administered. 
Consequently, timely administration of naloxone during overdose is crucial for reducing mortality associated 
with opioid overdose. Distribution of naloxone to laypersons may reduce the time taken to give naloxone and 
thus reduce overdose mortality. 
Key question
Should naloxone be distributed to people who are likely to witness an opioid overdose?
Systematic review
Of the 5594 studies screened, none fulfilled the eligibility criteria. 
Summary of the evidence 
There were no studies that met the inclusion criteria for the review. 
Benefits and harms
Although there were no studies that met the criteria for low risk of bias set by the systematic review, there 
were 20 studies reporting some data on the provision of naloxone to people likely to witness an opioid overdose 
(“take-home” naloxone), which are summarized in Annex 2. More than 50 000 doses of naloxone have been 
distributed in the USA alone. Based on this data, the estimated mortality rate in overdoses witnessed by 
people who have been given naloxone is 1.0% (95% CI 0.83% to 1.21%). Although there was no comparator 
in these studies, the mortality rate of opioid overdose where community use of naloxone was not available 
has been estimated at 2–4% (9). These case series estimated the rate of acute opioid withdrawal at 7.6% 
following naloxone (4.9% to 10.2%), and the only adverse event reported being seizures which occurred in 
0.45% of overdose reversals. 
An interrupted-time-series analysis found that take-home naloxone was associated with lower overdose death 
rates (aRR 0.73 [0.57–0.91]) (48). 
The GDG judged the risk-benefit profile to be strongly in favour of naloxone distribution, due to its clear potential 
for saving lives and apparent low risk of significant adverse effects. While training was considered an important 
and intrinsic component of increased naloxone availability, the GDG cautioned against making it compulsory or 
institutionalizing it as there were concerns that lack of certified training may be used as a barrier to provision 
of naloxone. The panel noted that while minor adverse events from naloxone administration (such as vomiting 
and opioid withdrawal) were not uncommon, serious adverse events were extremely rare. 
Values and preferences
Naloxone distribution programmes may assist in the timely treatment of overdose where emergency help is 
unavailable or unlikely to reach the overdosing person in time (57, 61, 62).
The online values-and-preferences survey (see Annex 6) revealed a strong preference for receiving naloxone and 
resuscitation after overdose, including from lay first responders unknown to the person who had overdosed. 
Non-medically trained respondents indicated a high level of willingness to provide naloxone and resuscitation to 
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strangers who had overdosed. Those able to prescribe medication showed a strong preference for prescribing 
naloxone to both people at risk of overdose and people likely to witness an overdose. The majority indicated 
preparedness to carry naloxone with them at all times. Health care workers confirmed that naloxone was often 
not currently available in medical settings.
Participants in the in-depth interviews were also strongly in favour of wider naloxone availability.
Costs and resource use
The panel judged naloxone distribution and training interventions to be currently cost-effective across a range 
of economic settings for the treatment of opioid overdose in the community. Approximately 20% of doses 
distributed in observational studies are reported to be used. Naloxone was used in approximately 70% of the 
overdoses witnessed by laypersons provided with take-home naloxone (50–54). However, the panel noted that 
while naloxone is currently affordable, there is a possibility that new formulations targeted for community use 
will be developed, and that should the price rise considerably this may be a less cost-effective intervention. 
The panel noted the lack of analyses or modelling studies to guide assessment of the cost-effectiveness of 
take-home naloxone programmes for people using prescribed opioids.
Feasibility
Naloxone distribution appears feasible in most socioeconomic settings. However, the panel noted that 
prescription regulations in different jurisdictions may be a barrier to provision of take-home naloxone.
RECOMMENDATION  (KEY QUESTION 1)
People likely to witness an opioid overdose should have access to naloxone and be instructed in its administration 
to enable them to use it for the emergency management of suspected opioid overdose. 
Strength of recommendation: Strong      Quality of evidence: Very low
REMARKS
• There may be both legal and policy barriers to the access and use of naloxone by lay first responders, which may 
need to be reviewed in order to implement this recommendation.
• In addition to the use of naloxone, emergency care of suspected opioid overdose should include ventilation support, 
airway management and management of withdrawal effects (specific emergency-care measures are described in 
Recommendation 3). While comprehensive training in opioid overdose and resuscitation is desirable, basic training 
can enable the effective emergency use of naloxone and the lack of more extensive training should not impede its 
use in the community. There are many training programmes available reflecting local contexts and needs.
• The panel notes that the people at risk of overdose and those likely to witness an overdose may vary according to 
the local context (see examples in Table 3).
• Access to naloxone implies that the price remains affordable. The GDG made a strong recommendation for the use 
of naloxone based on current prices but note that this could change if prices rise drastically. 
Decision on strength of recommendation: The GDG determined that this recommendation should be strong despite 
the very low quality evidence due to the life-saving nature of the intervention and the apparent absence of significant 
harm. The panel also noted that this is a feasible intervention, highly valued by those at risk of opioid overdose and 
those likely to witness an opioid overdose in the community.  
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Key questions 2 and 3 – formulation and dose of naloxone (see 
Annex 3 for details)
Evidence for key question 2 on naloxone dose and key question 3 on naloxone route of administration were 
considered together, given the potential for an interaction between dosing and route of administration.
Background
Naloxone, formulated as naloxone hydrochloride, is available in 0.02 mg, 0.4 mg and 1 mg per 1 ml vials, 
2 mg/1 ml, 2 mg/2 ml, 2 mg/5 ml prefilled syringes, and a 4 mg/10 ml multi-dose vial. It is currently not under 
patent and available through generic manufactures. The intravenous (IV) route requires intravenous access. 
Intramuscular (IM) and subcutaneous (SC) routes do not require IV access, but require a needle. The intranasal 
(IN) route does not require a needle; typically a syringe containing naloxone (either a prefilled syringe or drawn 
up from a vial) is attached to a mucosal atomization device which generates a fine mist of naloxone containing 
solution when the syringe plunger is pressed. To date, there has been no formulation of naloxone registered 
specifically for IN use. 
The naloxone dose needed to achieve reversal of opioid overdose is a function of the dosage of administered 
opioid, other concurrently administered drugs (particularly sedatives) and a variety of other factors. Given the 
uncertainties surrounding the dose of opioid taken, and the presence of other drugs, several international 
guidelines recommend titration of naloxone until clinical reversal is apparent (63–65).
Key question (combined)
What formulation and dosage of naloxone should be used in the initial management of opioid overdose, including 
by lay responders, in the pre-hospital setting?
Systematic review
Of the 5594 studies screened, two RCTs fulfilled the eligibility criteria (66, 67). Both were field-based RCTs 
conducted in Victoria, Australia, comparing use of intranasal versus intramuscular naloxone by paramedics in 
people with suspected opioid overdose in pre-hospital settings.
TABLE 3. EXAMPLES OF PEOPLE AT HIGHER RISK OF OVERDOSE AND PEOPLE LIKELY TO 
WITNESS AN OVERDOSE
People at higher 
risk of overdose
• people with opioid dependence, in particular those with reduced tolerance (following 
detoxification, release from incarceration, cessation of treatment)
• people who inject opioids
• people who use prescription opioids, in particular those on higher doses 
• people who use opioids in combination with other sedating substances
• opioid users with other significant medical conditions (HIV, liver or lung disease, 
depression)
• household members of people in possession of strong opioids 
People likely 
to witness an 
overdose
• people at risk of an opioid overdose, their friends and families 
• people whose work brings them into contact with people who overdose (health care 
workers, police, emergency service workers, people providing accommodation to people 
who use drugs, peer education and outreach workers) 
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Evidence to recommendation
Summary of findings
Meta-analysis of the two eligible RCTs found no difference between the administration of intranasal naloxone 
(initial dose 2 mg) versus intramuscular naloxone (initial dose 2 mg) for opioid overdose. There was no 
difference in the rates of overdose complications (relative risk (RR) 0.36 [0.01 to 8.65]), overdose morbidity 
(RR 0.85 [0.71 to 1.03]), opioid withdrawal reaction to naloxone (RR 0.42 [0.1 to 1.65]) or time to opioid reversal 
(mean difference (MD) 1.05 higher [0.81 lower to 2.91 higher]). There were no deaths in either study. Ease of 
administration was not estimable.
There were no studies examining IV administration compared to IN or IM naloxone administration. 
There were no studies comparing different doses or dosing regimens of naloxone (such as titration versus 
single dose). 
Benefits and harms
The panel judged the efficacy of naloxone in the treatment of opioid overdose to be largely independent of the 
route of administration. The panel noted that IV administration may not be appropriate for use in the community. 
The extra time required to achieve intravenous access and administration compared with intramuscular or 
intranasal administration was also noted. An added benefit of intranasal preparations was that because they 
do not require a needle, they eliminate the risk of needlestick injury.
The panel noted the evidence from observational studies that initial doses in the range of 0.4 to 2 mg have 
been used successfully for reversing opioid overdose in the community, and that on occasions, two or more 
doses were required. The possibility of adverse effects (including prolonged opioid withdrawal and seizures) 
with the use of naloxone doses higher than 2 mg was considered a potential harm. 
Values and preferences
Published surveys have shown a high degree of preparedness by non-medically trained persons to administer 
naloxone to family members, friends and strangers who have overdosed, with a preference for the intranasal 
formulation (68, 69). This was confirmed in the online survey conducted for these guidelines. Observers also 
informed the GDG meeting that people who have overdosed prefer to receive the smallest effective dose to 
avoid withdrawal symptoms, even if this means requiring a second dose. 
Costs and resource use
The panel judged the costs associated with the various routes of administration to be currently low, noting some 
uncertainty of the pricing of specifically designed products for lay administration currently under development.
Feasibility
While judging naloxone administration in a variety of dosages to be feasible in all settings, the panel noted IV 
administration would be less appropriate for laypersons, where preference for IM or IN modes may be more 
appropriate. 
Intranasal use of naloxone is currently an improvised, “off-label” method of administration which has not 
passed through regulatory procedures.
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RECOMMENDATION 2 (KEY QUESTIONS 2 AND 3)
Naloxone is effective when delivered by intravenous, intramuscular, subcutaneous and intranasal routes of 
administration. Persons using naloxone should select a route of administration based on the formulation available, 
their skills in administration, the setting and local context. 
Strength of recommendation: Conditional      Quality of evidence: Very low
REMARKS
Route of administration
• The GDG recognizes that the IV route is appropriate and effective in medical settings.
• Parenteral use of naloxone (IV, IM, SC) requires sterile injection equipment. 
• The capacity of the nasal mucosa to absorb liquids is limited, so if the intranasal route of administration is to be 
used, concentrated forms of naloxone should ideally be used.
• The GDG has made this recommendation fully aware that the intranasal route is currently an off-label (non-licensed) 
route.
• Affordability may dictate the preferred route in particular contexts.
Dosage
• The choice of initial dose will depend on the formulation of naloxone to be used and the context. 
– In medical settings dose selection is not generally an issue as dose titration is standard practice. In non-medical 
settings dose titration is not so easily accomplished and higher initial doses may be desirable. 
– The context also dictates the total amount of naloxone made available to non-medical responders. More than 
one dose may need to be available in a non-medical setting. The initial dose should be 0.4 mg–2 mg, targeting 
recovery of breathing. In most cases 0.4–0.8 mg is an effective dose. It is important to provide sufficient naloxone 
to supplement the initial dose, as necessary.
– Intranasal delivery may require a higher dose. It should be noted that the commonly used method of intranasal 
administration is to spray 1 ml of the 1 mg/ ml formulation of naloxone into each nostril with an atomizer 
connected to a syringe.
• Where possible, efforts should be made to tailor the dose to avoid marked opioid withdrawal symptoms. The GDG 
notes that higher initial doses above 0.8 mg IM/IV/SC are more likely to precipitate significant withdrawal symptoms.
• A more complicated situation arises where there has been an overdose of a combination of drugs. In this situation 
naloxone is still beneficial for reversing the opioid intoxication component of the overdose.  
• It is essential that expert professional assistance be sought as soon as possible. Even in the case of opioid overdose, 
a person may not respond to naloxone if other drugs have been taken.
Decision on strength of recommendation: The GDG decided to make this a conditional recommendation 
because, while there was certainty that the benefits outweighed the harms and that the end-users favoured this 
recommendation, there was uncertainty about the costs of intranasal naloxone, as this is currently an “off-label” use.   
Key question 4 – cardiopulmonary resuscitation (see Annex 4 for 
details)
Background
Until recently, the standard approach to cardiopulmonary resuscitation (CPR), regardless of aetiology, has been 
to clear the airway, provide rescue breathing and perform chest compression (the “ABC” approach – airway, 
breathing, circulation). However, in the past decade there has been concern that bystanders are not willing or 
able to provide rescue breathing effectively and that this may delay the use of chest compression. As a result, 
some international guidelines now recommend that layperson bystanders responding to cardiac arrest use 
chest compression only cardiopulmonary resuscitation (COCPR) (63, 65). 
The cardiac arrest seen in opioid overdose occurs as a result of progressive respiratory failure and metabolic 
disturbances. Because the aetiology in this type of cardiopulmonary arrest is primarily respiratory in origin, 
provision of traditional resuscitation, using rescue breathing as well as chest compressions, may be needed. 
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Key question
Should the resuscitation response to suspected opioid overdose, including by layperson bystanders, be based 
on standard CPR or chest compression only CPR?
Systematic review 
Of the 5594 studies screened, none fulfilled the eligibility criteria set initially, but there were a number of trials 
comparing CPR to COCPR for out-of-hospital cardiac arrest of unspecified origin.
Evidence to recommendations
Summary of findings
Since there have been no studies comparing CPR to COCPR in the management of opioid overdose, the quality 
of direct evidence in favour of one approach over the other is very low. 
Benefits and harms
A number of trials provide indirect evidence related to the benefits and harms of CPR and COCPR in opioid 
overdose. A study in Melbourne of bystander-administered CPR for heroin overdose found the provision of 
CPR, compared with no CPR, was associated with a lower rate of hospitalization (13.9% vs. 17.7% P<0.05) (70).
A meta-analysis of CPR versus COCPR for non-specific arrest found COCPR to be associated with increased 
survival compared with standard CPR (RR 1.22 [1.01–1.46]) (71), however this did not identify the sub-population 
of interest – people with opioid-induced cardiac arrest. 
Chest injuries from CPR are common, but age dependent. The incidence of rib fractures varied from 12.9% 
to 96.6% while for sternal fractures it was 1.3% to 43.3%, but these do not appear to affect survival (76). The 
incidence of fractured ribs is lower in younger populations (76).
The panel judged the benefits of any CPR to outweigh the risks, including due to its misapplication. The panel 
judged early naloxone provision to be a fundamental component of the CPR response in suspected opioid 
overdose. While noting the trend for the use of COCPR in non-opioid-induced cardiac arrest, the panel concluded 
that, in suspected opioid overdose, there is a clear benefit from effectively administered rescue breathing in 
combination with chest compressions and a potential harm from not providing rescue breathing. Given the 
clear and strong benefits of naloxone, the panel also advised that the resuscitation approach used should be 
one that does not delay the initial administration of naloxone.  
Values and preferences
The observational studies reviewed in Annex 2, report that lay first responders are willing to, and do, administer 
CPR, including rescue breathing. Respondents to the online values-and-preferences survey indicated a high level 
of preparedness to give both chest compressions and rescue breathing to people experiencing opioid overdose. 
There was a preference for use of barrier devices when providing rescue breathing. People at risk of overdose 
indicated they wished to receive chest compressions and rescue breathing if naloxone was not available.  
Costs and resources 
It was noted that while training is required for bystanders to correctly implement CPR, performance of all forms 
of CPR consumes few resources.
Feasibility
All forms of CPR were shown to be feasible in all studies, notwithstanding potential cultural issues with rescue 
breathing, including mouth-to-mouth resuscitation.
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RECOMMENDATION 3 (KEY QUESTION 4)
In suspected opioid overdose, first responders should focus on airway management, assisting ventilation and 
administering naloxone.   
Strength of recommendation: Strong      Quality of evidence1: Very low
REMARKS
Because the key feature of opioid overdose is respiratory arrest, ventilation is a priority. While recognizing there are 
different protocols in different parts of the world, the GDG suggests the following steps in resuscitating an individual 
with suspected opioid overdose.
• Apply vigorous stimulation2, check and clear airway, and check respiration – look for chest rising and falling.
• In the presence of vomit, seizures or irregular breathing, turn the patient on their side, and, if necessary, clear the 
airway of vomit.
• In the absence of regular breathing provide rescue ventilation and administer naloxone. 
• If there are no signs of life, commence chest compressions.
• Re-administer naloxone after two to three minutes if necessary.  
• In all cases call for professional assistance.
• Monitor the person until professional help arrives. 
• Where available, CPR mouth barriers should be used for rescue ventilation. 
Decision on strength of recommendation: The GDG determined that the recommendation should be strong despite the 
very low quality of the evidence because of the life-saving nature of CPR, including rescue breathing, in suspected 
opioid overdose in the community, and the low likelihood of resuscitation-induced harm. The panel also noted the 
feasibility of, and strong preferences in favour of CPR, including rescue breathing, expressed both by those at risk of 
overdose and those likely to witness an opioid overdose. 
1 The quality of evidence refers to the clinical trial evidence on the key question (comparing different approaches to resuscitation in opioid overdose) rather than the 
clinical trial evidence for resuscitation per se.
2 The most common way of applying vigorous physical stimulation to someone who is not responding to verbal stimulation is to rub the person’s sternum (breast bone) 
with one’s knuckles.
Key question 5 – post-resuscitation care (see Annex 5 for details)
Background
For the purpose of these guidelines, post-resuscitation care refers to the period immediately following the 
successful reversal of opioid overdose with naloxone. Successful reversal is indicated by the full restoration 
of consciousness, or effectively “walking and talking normally”.
The half-life of naloxone is substantially shorter than the half-life of some opioids, resulting in a risk of rebound 
toxicity when the naloxone “wears off”. Consequently, post-resuscitation care in long-acting overdoses may 
need to be prolonged. 
Key question
What should be the response to opioid overdose after the administration of naloxone and successful reversal 
of opioid overdose in the community, including by lay first responders?
Systematic review
Of the 5594 studies screened, none fulfilled eligibility criteria regarding the subsequent management of 
overdose with short-acting opioids following reversal with naloxone. 
One RCT assessed the management of methadone (a long-acting opioid) overdose in opioid-naïve individuals 
using naltrexone, a specific sub-population at risk of overdose from long-acting opioids. As it was agreed 
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during the meeting to limit the scope of the guidelines to opioid overdose care in the community, the use of 
naltrexone, which is not considered appropriate for lay administration, was excluded from further consideration 
in these guidelines.
Five observational studies relevant to the question were identified. These studies, which investigated 
appropriate criteria for discharge from care or observation, were confined to post-hoc examinations of ambulance 
or emergency department datasets, cross-referencing specific medical examiner databases and were all from 
high-income countries (see Annex 5). 
Evidence to recommendations
Summary of findings
Five observational studies assessed mortality risk following opioid overdose reversal with naloxone by 
ambulance staff and discharge on-scene. One prospective study which linked pre-hospital emergency care and 
forensic examiners’ databases over 10 years, identified 3245 individuals treated for opioid overdose, 2241 of 
whom were released on-scene. Rebound opioid toxicity was identified in three of 14 deaths recorded within 
48 hours of receiving naloxone (0.13% – 3/2241 from rebound opioid toxicity, 0.62% all-cause mortality) (77). A 
further three retrospective studies linking emergency medical services (EMS) and forensic examiners’ datasets 
reported no deaths within 12 hours of naloxone reversal in 1661 pre-hospital opioid overdoses where the 
individuals were either discharged on-scene or refused further observation (78–80). A retrospective review of 
hospital emergency department admissions following transportation after being treated for opioid overdose 
reported that 97% of 444 transported individuals were discharged from care without further intervention (81).
Benefits and harms
The panel decided that there is a potential for harm from rebound opioid toxicity following reversal of opioid 
overdose with naloxone in the community if the person who has overdosed is left unsupervised. This risk of 
harm can be reduced considerably if the first responder remains with the person who has overdosed until after 
the effects of naloxone have “worn off” and monitors their breathing and level of consciousness. 
A normal level of consciousness (Glascow Coma Scale [GCS] score 15), “walking and talking” normally and 
normal breathing pattern (respiratory rate > 10) indicate recovery. 
The panel did not make a recommendation on subsequent management of long-acting opioid overdose as such 
overdoses should be managed in hospitals and the scope of these guidelines was limited to the management 
of opioid overdose in the community setting.
Values and preferences
The majority of street-based drug users report staying with people who have overdosed (69). Family members 
and friends of people at risk of overdose also indicated they would stay with the person who has overdosed. 
People who come across people who have overdosed in the course of their work would expect to do the same.
Costs and resources 
The panel judged that there are minimal financial consequences of remaining with a person recovering from 
opioid overdose for several hours. On the other hand, routine transfer to hospital requires considerable use 
of resources. 
Feasibility
While noting that all studies concerning the post-naloxone management of short-acting opioid overdose have 
been conducted in high-income countries, the panel agreed that discharge on-scene following opioid overdose 
recovery is feasible in most settings. The panel was not able to assess the feasibility of layperson observation 
and “discharge” following recovery as no data was available to evaluate this component of care.
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RECOMMENDATION 4 (KEY QUESTION 5)
After successful resuscitation following the administration of naloxone, the affected person should have their level 
of consciousness and breathing closely observed until they have fully recovered.  
Strength of recommendation: Strong      Quality of evidence: Very low
REMARKS
• This recommendation is made with knowledge of the extended duration of opioid overdose, especially with the 
variety of longer-acting opioids and opioid formulations in current usage. It is critical to appreciate that the witness 
cannot tell what the length of action will be without observing the person who has overdosed. It is important to 
increase awareness of the need to remain with the person who has overdosed.
• Ideally, observation should be performed by properly-trained professionals. This applies particularly where the 
overdose is due to the use of long-acting opioids. The period of observation needed to ensure full recovery is at 
least two hours, following overdose from short-acting opioids such as heroin. It may be longer where a longer acting 
opioid has been consumed. 
• If a person relapses into opioid overdose, further naloxone administration may be required.
• The definition of ‘fully recovered’ is a return to pre-overdose levels of consciousness two hours after the last dose of 
naloxone.  
• After the overdose has been reversed, the person who has overdosed should be reminded not to use opioids and 
other drugs that will interfere with their recovery from the overdose.
• It is important to ensure that the person who is resuscitated understands what happened and the risks of what might 
happen next. It should also be recognized that this is “a teachable moment” – an opportunity to offer discussion of a 
range of treatment options and to train the person in the prevention and management of any future overdoses.
Decision on strength of recommendation: The GDG determined that this should be a strong recommendation despite 
the low quality of evidence due to the ethical barriers to testing this with randomized control trials. The GDG is aware 
that  the short half-life of naloxone, coupled with difficulty ascertaining the dose and type of opioid taken, means 
that naloxone may cease to be effective before the person has fully recovered but the simple nature of the proposed 
intervention is unlikely to result in any harm, and the willingness of people likely to witness an overdose to remain with 
people who have overdosed is  documented. 
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RESEARCH PRIORITIES AND GAPS 
Epidemiology/strategic information
There is a need for better epidemiological data as recent estimates of overdose incidence are restricted to high-
income countries. Monitoring systems of fatal and non-fatal overdoses, as well as routine toxicology analysis 
of possible overdose deaths will facilitate this.  
There is uncertainty about the magnitude of the benefit from a wider availability and lay use of naloxone and 
resuscitation, including the impact on mortality and health-care utilization. Such data, if combined with data on 
the cost of implementing these recommendations, would be useful for cost-effectiveness and cost-benefit 
analyses. Suggested study designs include monitoring the proportion of witnessed overdoses that are fatal and 
the proportion of fatal overdoses that are witnessed following the increased availability and use of naloxone 
as well as controlled prospective studies between sites that have increased availability of naloxone and those 
that have not. 
Route of administration and dose of naloxone in the pre-hospital setting
Questions remain about the optimal dosing and formulation for the intranasal route of administration. This could 
be addressed by a pharmacokinetic study and tested in a RCT. 
The preference of people who have overdosed for lower initial doses could be tested in a RCT, comparing time 
to response, need for subsequent dose and adverse effects. 
It is not clear how much naloxone should be carried by lay first responders to cover all likely overdoses. This 
could be addressed by monitoring the doses used in the field. 
Resuscitation in the pre-hospital setting by lay first responders
It is unclear if resuscitation is needed in combination with naloxone or only if there is no response to naloxone. 
The role of rescue breathing for lay responders in opioid overdose is inadequately understood given that 
hypoventilation and subsequent hypoxia is the causative mechanism. 
Post-resuscitation care in the pre-hospital setting 
Relative and absolute indications for transfer to hospital following opioid reversal remain unclear, in particular 
in the context of suspected long-acting opioid use. 
In addition, key management steps in the treatment of complex overdoses (such as those due to buprenorphine 
and benzodiazepines) remain poorly understood, including the role of benzodiazepine reversal agents.
Naltrexone has been investigated in the management of accidental long acting opioid overdose in the opioid 
naiive. While naltrexone was not considered appropriate for lay administration in these guidelines, it may have 
a role in hospital settings. There has been limited investigation of the opioid antagonist nalmefene, which may 
have a role as a longer acting alternative to naloxone.
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PLANS FOR DISSEMINATING, ADAPTING AND 
IMPLEMENTING THESE RECOMMENDATIONS
These recommendations will be used to provide guidance on the identification and management of opioid 
overdose in the community setting through a number of derivative publications, including model training 
materials and an implementation manual. These will be widely disseminated via the WHO regional and country 
offices, collaborating centres, professional organizations and partner agencies.
These recommendations will be adapted for the field by developing suitable training materials in consultation 
with regional, national and local stakeholders. Adaptation will include translation into appropriate languages 
and ensuring that the interventions are acceptable in local sociocultural contexts and suitable for local health 
systems.
Evaluating the impact of these recommendations
The impact of these recommendations will be measured in the following ways:
 o the number of countries that implement programmes to increase the availability of naloxone and provide 
training in the management of opioid overdose to people likely to witness an opioid overdose;
 o the number of countries in which naloxone is available for out-of-hospital care by paramedics;
 o the WHO survey of resources for the prevention and treatment of substance use disorders;
 o the number of countries that produce guidelines on the use of naloxone in the management of opioid 
overdose in the pre-hospital setting consistent with these WHO guidelines;
 o an assessment of the number of references to the WHO guidelines in the medical literature;
 o measurement of opioid overdose deaths and the proportion of witnessed opioid overdoses that are fatal, 
both where naloxone has been provided and where naloxone has not been provided.
Review date
It is not expected that these recommendations will need to be reviewed until 2017. However, developments in 
the field will be continually monitored and should there be significant changes in practice and/or the evidence 
base that affect any of the recommendations, review may be undertaken earlier.
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ANNEX 1  
SYSTEMATIC REVIEW SEARCH STRATEGY
Methods
Inclusion criteria
Study type
Systematic reviews 
Randomized control trials
Controlled prospective studies
Published in a peer-reviewed journal, or presented as an abstract at a scientific conference, between 1 January 
1966 and 1 January 2014
Populations
People who use opioids (oral or parenteral)
Types of interventions 
Defined by PICO question
Types of comparison
Defined by PICO question
Outcome measures
Selected by GDG for each question and ranked by importance
Search methods
Electronic searches
The following electronic databases were searched:
 o Medline (1966 to present)
 o EMBASE (1980 to present)
 o Cochrane library
 o WHO library (2000 to present)
 o Clinicaltrials.gov
 o International Clinical Trials Registry Platform
 o Psychinfo (1980 to present)
 o Cinahl (1982 to present)
 o Toxline (1965 to present)
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Search Strategy (Pubmed) 
# Searches Results
1 "Drug Overdose"[Mesh] OR overdose* OR  OD [TIAB]  OR "over dose" [TIAB] OR "over 
dosage" [TIAB] OR "over dosed" [TIAB]  OR “over dosing” [TIAB]
23090
2 "toxicity" [Subheading] OR "Toxicity Tests"[Mesh] OR toxicity [TIAB] OR poisoning [TIAB] 
OR "Poisoning"[Mesh] OR  "poisoning" [Subheading]        
695864
3 "Heroin"[Mesh] OR "Heroin Dependence"[Mesh] OR Opiate*[TIAB]    OR Opioid*[TIAB]    OR 
Diamorphine [TIAB] OR Diacetylmorphine [TIAB] OR Diagesil [TIAB] OR Diamorf [TIAB] 
OR Morphine [TIAB] OR Diacetylmorphine Hydrochloride [TIAB] OR Heroin [TIAB] OR 
"Opioid-Related Disorders" [MH] OR "Opium"[Mesh] OR Opium [TIAB] OR hydrocodone 
[TIAB] OR Buprenorphine [TIAB] OR codeine [TIAB]    OR dextroproxyphene [TIAB]  OR 
fentanyl [TIAB] OR hydromorphone [TIAB]  OR meperidine [TIAB]  OR morphine [TIAB] 
OR morphine [MH] OR oxycodone [TIAB] OR pentazocine [TIAB] OR sufentanil [TIAB] 
OR tramadol [TIAB] OR hydrocodone [MH] OR buprenorphine [MH] OR codeine [MH] 
OR extroproxyphene  [MH] OR fentanyl  [MH] OR hydromorphone [MH]  OR meperidine  
[MH] OR  opium [MH] OR oxycodone [MH] OR pentazocine  [MH] OR sufentanil [MH] OR 
tramadol [MH]
141562
4 (#1 OR #2) AND #3 25487
5 Naloxone [MH] OR naloxone [TIAB]   OR antioplaz [TIAB] OR  en 1530 [TIAB] OR  en 15304 
[TIAB] OR  en1530 [TIAB] OR  en15304 [TIAB] OR  l n allyl 14 hydroxynordihydromorphinone 
[TIAB] OR  maloxone [TIAB] OR  mapin [TIAB] OR  n allyl 7  8 dihydro 4 
hydroxynormorphinone [TIAB] OR  n allylnoroxymorphone hydrochloride [TIAB] OR  
naloxone [TIAB] OR  nalone [TIAB] OR  nalonee [TIAB] OR   narcan[TIAB] OR  narcan 
neonatal [TIAB] OR  narcanti [TIAB] OR  narcon [TIAB] OR  narvcam [TIAB] OR  naxone 
[TIAB] OR  zynox [TIAB] OR Nalone [TIAB] OR Naloxonratiopharm  [TIAB]  OR MRZ-
2593[TIAB]  OR MRZ 2593[TIAB]  OR MRZ2593[TIAB]  
28476
6 "Flumazenil"[Mesh] OR    Flumazepil  [All fields ] OR     Romazicon [All fields ]  OR   Lanexat 
[All fields ]  OR  Anexate [All fields ]  OR “Ro 15 1788” [TIAB] OR  “Ro 151788” [TIAB]  OR  
mazicon [TIAB]   OR  “ym 684” [TIAB]  OR  ym684 [TIAB]
4338
7 "Cardiopulmonary Resuscitation"[Mesh]  CPR [TIAB]  OR  Code Blue [TIAB]  OR  Mouth-to-
Mouth [TIAB]   OR    Basic Cardiac Life Support  [TIAB]   OR  “assisted ventilation”  [TIAB]   
OR “ bag valve mask ventilation” [TIAB]    OR  “pocket mask “  [TIAB]   OR  resuscitation 
[TIAB]  OR "Heart Massage"[Mesh] OR heart massages [TIAB] OR Heart massage [TIAB] 
OR cardiac massage  [TIAB] OR cardiac massages [TIAB]
42178
2 #5 OR #6 OR #7 72661
9 #4 AND #8 23604
10 "animals" [Mh] NOT ("animals"[MH] AND "humans" [MH]) 3854040
11 #9 NOT #10 7084
12 randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized [tiab] 
OR placebo [tiab] OR  randomly [tiab] OR trial [tiab] OR  groups [tiab] OR Random* 
[TIAB]  OR “cohort studies” [MH] OR cohort* [TW] OR “controlled clinical trial” [PT] OR  
“epidemiologic methods” [MH] OR “case-control studies” [MH] OR (case [TW]  AND  
control*[TW]) OR (case [TW] AND series [TW])
5554641
13 #11 AND #12 2730
Search terms
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Data collation and extraction 
Selection of studies
The initial screening was carried out by a single reviewer who inspected the search hits by reading titles 
and abstracts. Following this, each potentially relevant study located in the search was obtained in full text 
and assessed for inclusion independently by two reviewers. In doubtful or controversial cases, all identified 
discrepancies were discussed in order to reach consensus on all items.
Citations identified through computer database searching were initially screened into the following categories:
Yes – for articles clearly meeting the inclusion criteria for the review. 
Pull to check – for articles which may meet the inclusion criteria; the full text of the article must be reviewed 
before final decision about inclusion can be made.  
No – for articles clearly not meeting the inclusion criteria for the review; no further consideration is necessary.
Other evidence referred to in the guidelines 
Additional scientific literature is referred to in the guidelines to provide background and contextual information, 
and to assist in the completion of the balance between benefits and harms, values and preferences, and 
feasibility sections of the “evidence to recommendations” profiles. This evidence was not searched for 
systematically. 
A separate online survey and key informant interviews were also conducted to inform the values and 
preferences section (see Annex 6).
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ANNEX 2  
KEY QUESTION 1 – EVIDENCE PROFILE AND 
DECISION TABLE
Key question 1
Should naloxone be distributed to people who are likely to witness an opioid 
overdose?
PICO formulation of key question for evidence synthesis
Population:  People likely to witness an opioid overdose
Intervention:  Provision of naloxone, and training in its administration in the management of opioid overdose
Comparison:  Treatment as usual (no provision of naloxone outside medical settings)
Outcomes:  (see below)
OUTCOMES SELECTED AND RANKED BY THE GDG FOR KEY QUESTION 1
Outcome Importance
Overdose mortality Critical
Overdose complication (such as aspiration) Critical
Overdose morbidity (prolonged adverse outcome of opioid overdose) Critical
Time to administer naloxone Critical
Time to opioid overdose reversal Critical
Opioid withdrawal reaction to naloxone Important
BBV transmission through unsafe injection Important
Unsafe injection related injury Important
Adverse effect of resuscitation Important
Psychosocial intervention / referral to treatment post overdose Important
Evidence
Of the 5594 studies screened, no studies fulfilled the eligibility criteria:
 o systematic reviews – none
 o randomized controlled trials – none
 o controlled prospective studies – none.
Other evidence
Although no studies met the eligibility criteria, observational evidence identified in the systematic search that 
met all PICO criteria other than the comparison group/study design were examined for information on the 
outcomes under consideration (see Tables 4, 5 and 6, below).
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ta
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m
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 o
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ne
d 
in
 
ov
er
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 m
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em
en
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le
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 m
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m
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ne
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at
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po
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ed
 re
ve
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al
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ffe
re
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 p
eo
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re
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N
o 
de
at
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ca
se
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lo
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ne
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ip
ita
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w
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aw
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m
pt
om
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 c
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 c
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r c
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al
ox
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w
er
e 
in
vo
lv
ed
 in
 2
1 
of
 th
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ve
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 b
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os
al
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m
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at
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, b
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r p
eo
pl
e 
w
ho
 
us
ed
 n
al
ox
on
e 
su
pp
ly
 w
er
e 
no
t i
ni
tia
lly
 
en
ro
lle
d 
in
 th
e 
pr
og
ra
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sc
o,
 U
SA
O
pi
oi
d 
us
er
s 
(N
=1
94
2)
Ta
ug
ht
 m
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O
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, p
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 c
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 m
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 b
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 b
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 c
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 m
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 p
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 d
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at
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. C
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R
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R
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t r
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itn
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pr
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re
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 m
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, c
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at
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 m
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) p
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itn
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l o
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 m
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re
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itn
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 m
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 m
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 re
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 p
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 d
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 p
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 re
ce
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 C
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 c
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 c
as
e,
 
na
lo
xo
ne
 s
to
ra
ge
 a
nd
 m
an
ag
em
en
t o
f 
na
lo
xo
ne
 in
du
ce
d 
w
ith
dr
aw
al
 s
ym
pt
om
s;
 
2 
x 
0.
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at
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 C
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 re
po
rt
ed
; n
o 
ad
ve
rs
e 
ef
fe
ct
s 
re
po
rt
ed
Th
e 
pr
og
ra
m
m
e 
ha
d 
a 
hi
gh
 re
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itn
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 m
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 o
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ke
n 
to
 h
os
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t t
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 p
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f c
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t i
ts
 u
se
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m
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 p
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itu
at
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 c
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 c
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 b
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m
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 c
om
m
on
ly
 
us
ed
 o
pi
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r o
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at
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r o
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at
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D
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 c
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 b
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at
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oc
ol
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r f
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l o
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 m
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 m
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 d
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 m
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 c
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 d
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 o
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fir
st
 a
nd
 m
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 d
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 c
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l d
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 b
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at
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 p
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 p
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l d
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ve
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 o
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 m
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r t
ra
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 p
re
fil
le
d 
sy
rin
ge
, 
sh
ar
ps
 b
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itn
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 re
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; C
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ra
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 c
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 p
ro
bl
em
 
fo
r r
ec
ru
itm
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t o
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SUMMARY OF FINDINGS TABLE – KEY QUESTION 1
Outcomes of overdoses witnessed by persons given naloxone and training in its use
Patient or population: Injecting drug users, peers, and family members
Settings: Community
Intervention: Naloxone distribution
Outcomes
Importance
(critical, 
important)
Illustrative comparative 
risks* (95% CI)
Studies  
No. of 
participants
(studies)
Quality 
of the 
evidence
(GRADE) CommentsControl 
Overdose 
witnessed by 
person given 
naloxone and 
training
Overdose 
mortality** 
Critical No 
control 
group
1.0%  
(0.83% to 1.21%)
15 studies1 1368 ⊕
VERY LOW
Overdose 
complication (such 
as aspiration)
Critical — — — — No such 
complications 
were reported 
although they were 
not specifically 
excluded
Overdose morbidity 
(prolonged adverse 
outcome of opioid 
overdose)
Critical — — — — No such outcomes 
were reported 
although they were 
not specifically 
excluded
Time to administer 
naloxone
Critical — — — — Not reported
Time to opioid 
overdose reversal 
Critical — — — — Not reported
Opioid withdrawal 
reaction to 
naloxone
Important No 
control 
group
7.6%  
(4.9% to 10.2%)
8 studies2 887 ⊕
VERY LOW
Psychosocial 
intervention/
referral to 
treatment post 
overdose
Important — — — — Not reported
Unsafe injection 
related injury
Important — — — — No unsafe 
injections were 
reported although it 
was not specifically 
reported as an 
outcome
Adverse effect 
of resuscitation 
(seizures)
Important No 
control 
group
0.45%  
(0.43% to 0.47%)
9 studies3 892 ⊕
VERY LOW
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Outcomes
Importance
(critical, 
important)
Illustrative comparative 
risks* (95% CI)
Studies  
No. of 
participants
(studies)
Quality 
of the 
evidence
(GRADE) CommentsControl 
Overdose 
witnessed by 
person given 
naloxone and 
training
BBV transmission 
through unsafe 
injection
Important — — — — ⊕
VERY LOW
No unsafe 
injections were 
reported although it 
was not specifically 
reported as an 
outcome
GRADE working group grades of evidence
 High quality: Further research is very unlikely to change our confidence in the estimate of effect. 
 Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
 Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
 Very low quality: We are very uncertain about the estimate.
* As uncontrolled case series, none of the studies produce an estimate of the effect size of the intervention and are not graded. They are, by default, the lowest grade 
of evidence.
**The overdose mortality is the crude proportion of deaths per witnessed overdose in the follow-up period of the study (generally 3-6 months), not an annual mortality 
rate.
1 Bennett (2012); Dettmer (2001); Dettmer (2001); Doe-Simkins (2009); Enteen (2010); Galea (2006); Leece (2013); Lopez Gaston (2009); Maxwell (2008); Mcauley (2009); 
Piper (2008); Seal (2005); Strang (2009); Wagner (2009); Walley (2013a).
2 Dettmer (2001 - Berlin); Doe-Simkins (2009); Enteen (2010); Galea (2006); Leece (2013); Lopez Gaston (2009); Maxwell (2008); Strang (2009).
3 Dettmer (2001; Dettmer (2001); Doe-Simkins (2009); Enteen (2010);  Galea (2006); Leece (2013); Lopez Gaston (2009); Maxwell (2008); Strang (2009).
Evidence to recommendation framework
Summary of evidence
There were no studies that met the inclusion criteria for the review.
Balance of benefits versus risks and harms
Benefits versus risks and harms
Although there were no studies that met the inclusion criteria of the systematic review, there were 20 studies 
reporting some data on the provision of naloxone to people likely to witness an opioid overdose (“take-home” 
naloxone). They describe more than 50 000 doses of naloxone distributed in the USA alone. Of those that were 
followed up, the average mortality rate in witnessed overdoses was 1.0% (0.83% to 1.21%). Although there 
was no comparator in these studies, the mortality rate following overdoses has previously been estimated at 
2–4% (9). An analysis of uncontrolled studies reveals that mortality rates are low in those administered naloxone 
(1.0% [0.83% to 1.21%]). The interrupted-time-series analysis found that take-home naloxone was associated 
with lower overdose death rates (aRR 0.73 [0.57 – 0.91]). 
Acute withdrawal syndrome from administration of naloxone is possible, although it is short lived (approximately 
15 minutes). Based on the observational studies reviewed, it is likely to occur in 7.6% (4.9% to 10.2%) of 
resuscitation attempts with naloxone in the community. The only other adverse outcome described in the 
observational studies reviewed are seizures, occurring in 0.45% of cases (0.43% to 0.47%). 
Values and preferences
Drug users’ peers are willing to intervene in overdose events (93), including administering naloxone (40). 
Observational studies performed in the USA report that following training, approximately 55% of trained 
participants witnessed an overdose (51, 55).  
Naloxone was used in approximately 70% (ranging from 60% to 80%) of the overdoses witnessed by naloxone-
trained laypersons (50–54).
Often people who witness an opioid overdose do not know which actions to take during witnessed overdoses 
(39, 94, 95). 
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An evaluation in New York of a peer naloxone programme reported that 97 of 118 participants (82.2%) said 
they felt comfortable to very comfortable using naloxone if indicated, while 94 of 109 (86.2%) said they would 
want a bystander to administer naloxone to them if they were overdosing (55).
There are case reports of self-administration of naloxone, including  reports of self-administration of intranasal 
naloxone (96).
A survey in 2003 of prescribers (physicians, physician’s assistants, nurse practitioners; n = 363) examining their 
willingness to prescribe naloxone for individuals at risk of overdose found 33.4% willing, 29.4% unsure and 
37.1% unwilling (97). A 2007 survey in USA found that 54% of physicians were unwilling to prescribe naloxone, 
though 23% had not heard of naloxone, suggesting that physician education might be necessary to improve 
knowledge and potential willingness (98).
Resource use
Wastage of naloxone appears low. One pilot study in central Asia found high usage rates (51%–83%) and 
low wastage rates (3.1%). A modelling study projected that wastage rates over four years would be between 
3%–14% (99).
Trained peers manage their take home naloxone carefully. In Scotland, a follow-up of 17 peers six months after 
having been given naloxone training reported all 17 still had their take home naloxone. Key-workers validated 
this in 15 individuals (100). There was no evidence of inappropriate use in the three cases where naloxone was 
administered.
In 2008, as part of the PONI (Preventing Overdose and Naloxone Intervention) project in Rhode Island, an 
estimate for the cost of treating overdose events in Rhode Island’s emergency departments (327 visits) was 
USD $88 288, with an additional minimum of $827 637 spent on hospital admissions related to overdose events. 
This yielded a total of $915 925 in overdose-related hospital costs for 2008, which the authors calculated could 
have been used to purchase over 61 000 kits of naloxone (102).
A peer distribution programme for naloxone in Toronto estimated if one life was saved out of 17 individuals 
administered naloxone for overdose, the programme would cost CAD $30 890–$46 335 per quality adjusted 
life year (QALY) gained (103).
A recent study found the distribution of naloxone to heroin users for lay-person administration to be cost-
effective in both the American and Russian context (104, 105). In the US scenario, naloxone distribution cost 
USD $438 per QALY gained (CI, $48 to $1706), and if heroin use was considered a net cost to society the cost 
per QALY gained increased to USD $2429 (CI, $1305 to $3986)(105). In the Russian context the cost per QALY 
gained was USD $94, but this cost would be higher if other societal costs of heroin use were included (106). 
Both cost-effectiveness analyses were based on modelled data.
The cost of naloxone varies enormously as it is a low-volume product and there is often only one distributor in 
a country. There are reports the cost of naloxone has gone up tenfold in recent years in the US. The website 
‘naloxone.info’ lists where naloxone may be purchased and prices for a 0.4 mg/ ml vial range from USD $0.38 in 
China to USD $0.51 in France to USD $50 in Sweden. One product which claims to be the only one specifically 
marketed for lay administration sells for US $27 for a pack containing one 2 ml prefilled syringe of 1 mg/ ml 
naloxone and two needles in a tamper proof case. 
Feasibility
Naloxone distribution appears feasible in most socioeconomic settings however there are a number of 
implementation issues, including the selection of participants, the training in overdose management and 
resuscitation, and legal issues in the distribution of a prescription medicine and the use of a prescription 
medicine by laypersons. 
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Identification of individuals for take home naloxone
Project Lazarus, in North Carolina, developed a set of criteria to screen individuals for eligibility for take home 
naloxone prescriptions. Thirteen indicators were identified. These included:
 o recent medical treatment for overdose
 o suspected non-medical use of opioids 
 o high dose prescription (> 100 mg morphine equivalence/day) 
 o methadone prescriptions for opioid naïve individuals
 o recent release from jail or drug treatment 
 o those in OST programmes 
 o any opioid prescription in those with a significant medical co-morbidity 
 o remoteness  
 o voluntary request (49).
Training
A number of studies documented significant increases in identification of overdose and correct indication for 
the administration of naloxone.
An RCT from the UK found knowledge and attitudes relating to overdose and naloxone administration improved 
to a greater extent in the intervention arm (structured training) compared to basic information only three months 
after completion of the intervention (60).
Published papers suggest the length and style of training necessary for naloxone distribution and administration 
is variable. Training can be delivered in a teaching session (54), friendly dialogue, group discussion or on a drop-
in basis (53). The session can take as little as 10 minutes (55–57) or as long as eight hours (58). Even very short 
trainings in naloxone indications can increase the accuracy in overdose identification.
In the Boston Public Health Commission naloxone distribution programme, while training for health professionals 
and employed staff was eight hours, bystander training was 15 minutes (56). 
A study of 70 individuals with opioid dependence in two sites in the UK found knowledge retention six months 
after training in the identification and treatment of overdose to be well preserved (101).
Legal
Naloxone is a prescription-only medication in most countries, but it is available over the counter in Italy. In the 
UK and the US (at the state level) special regulations for naloxone administration in an emergency situation 
and ‘good Samaritan’ laws are available to protect the physician and clients from legal action (107, 108). In the 
UK, naloxone is on a list of medications that can be legally administered by anyone in an emergency (109).
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DECISION TABLE: RECOMMENDATION 1
The GDG considered the following when making their decision on  the strength of the recommendation:
Factor GDG response
Is there high or moderate-quality evidence?
The higher the quality of evidence, the more likely is a strong recommendation. 
No
Is there certainty about the balance of benefits versus harms and burdens? 
In case of positive recommendations (a recommendation to do something), do the benefits 
outweigh harms? 
In case of negative recommendations (a recommendation not to do something), do the harms 
outweigh benefits?
Yes
Are the expected values and preferences clearly in favour of the recommendation? Yes
Is there certainty about the balance between benefits and resources being consumed?
In case of positive recommendations (recommending to do something) is there certainty that the 
benefits are worth the costs of the resources being consumed? 
In case of negative recommendations (recommending not to do something) is there certainty that 
the costs of the resources being consumed outweigh any benefit gained?
Yes
Strength of recommendation: the GDG decided to set the strength of the recommendation as ‘Strong’.
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ANNEX 3  
KEY QUESTIONS 2 AND 3 – EVIDENCE PROFILES 
AND DECISION TABLE
The close relationship between route of administration and dosage resulted in these two PICO questions 
overlapping substantially, so they were therefore considered together in the one review.
Key question 2
What formulation of naloxone should be used in the management of opioid 
overdose, including by lay responders, in the pre-hospital setting? 
PICO formulation of key question for evidence synthesis
Population:  People with opioid overdose in the community setting
Intervention:  Use of intranasal route of administration of naloxone
Control:  Use of intramuscular or subcutaenous route of administration of naloxone
Outcomes:  (see below)
OUTCOMES SELECTED AND RANKED BY GDG FOR KEY QUESTION 2
Outcome Importance
Overdose mortality Critical
Overdose complication (such as aspiration) Critical
Overdose morbidity (prolonged adverse outcome of opioid overdose) Critical
Opioid withdrawal reaction to naloxone Critical
Time to administer naloxone Critical
Time to opioid overdose reversal Critical
Ease of administration Critical
BBV transmission through unsafe injection Important
Unsafe injection related injury Important
Adverse effect of resuscitation Important
Psychosocial intervention / referral to treatment post overdose Important
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Key question 3
What dose of naloxone should be used initially in the management of opioid 
overdose?  
PICO formulation of key question for evidence synthesis
Population:  People with opioid overdose in the community
Intervention:  Single dose approach (use of 0.8 mg IM or higher as an initial dose, or equivalent dose 
  of alternative IV or IN formulation)
Comparison:  Titrated dose approach (use of 0.2-0.4 mg IM as an initial dose with view to repeating 
  the dose as needed, or equivalent dose of IV or IN formulation)
Outcomes:  (see below)
OUTCOMES SELECTED AND RANKED BY GDG FOR KEY QUESTION 3
Outcome Importance
Overdose mortality Critical
Overdose complic ation (such as aspiration) Critical
Overdose morbidity (prolonged adverse outcome of opioid overdose) Critical
Opioid withdrawal reaction to naloxone Critical
Time to opioid overdose reversal Critical
Time to administer naloxone Important
Psychosocial intervention / referral to treatment post overdose Important
BBV transmission through unsafe injection Not important
Unsafe injection related injury Not important
Background 
Naloxone hydrochloride is available in 0.02 mg, 0.4 mg and 1 mg per 1 ml vials, a 4 mg/10 ml multi-use vial, and 
2 mg/1 ml, 2 mg/2 ml and 2 mg/5 ml prefilled syringes for intravenous (IV), intramuscular (IM) and subcutaneous 
(SC) injection. It is currently not under patent and available as a generic product. 
The recommended dosage and route of administration provided by manufacturers’ product literature on 
management of opioid overdose is 0.4 to 2 mg via IM, IV or SC injection, repeated as necessary, up to a total 
dose of 10 mg. 
Current international recommendations on the dose and route of naloxone used for reversal of opioid 
overdose vary. The European Resuscitation Council Guidelines do not specify a route and recommend 
that initial doses of naloxone be 400 μg IV, 800 μg IM, 800 μg SC or 2 mg IN (65). The 2010 International 
Consensus on Cardiopulmonary Resuscitation Guidelines do not specify a dose but recommend naloxone be 
given intravenously or intramuscularly. Intranasal or tracheal routes may be used if conditions preclude IV or 
intramuscular administration (63). The American Heart Association Guidelines recommend dose titration (from 
0.04 mg or 0.4 mg upwards) and state naloxone can be given IV, IM, intranasally, and into the trachea (64). 
The above guidelines recommend that airway maintenance and assisted ventilation commence prior to the 
administration of naloxone for individuals in respiratory depression but not in cardiac arrest.
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The IV route requires intravenous access. Intramuscular and SC routes do not require IV access, but require 
a needle. The IN route does not require a needle – typically the syringe is attached to a mucosal atomization 
device.
The main adverse event associated with naloxone use for reversal of opioid intoxication is an acute opioid 
withdrawal syndrome, characterised by agitation and anxiety, nausea, myalgia and sweating (110). Avoidance 
(or reduction) of these symptoms is the rationale using a lower initial dosage (e.g.0.04 mg) titrated until effect 
is achieved with multiple boluses of increasing dosage (9, 111). The European Resuscitation Council guidelines 
recommend titration of the naloxone dose.
Naloxone pharmacokinetics and pharmacodynamics
A pharmacokinetic analysis of naloxone in six healthy male volunteers (median Ht 1.78, Wt 80 kg, age 25) 
monitored drug levels following: 1) 0.8 mg intravenous (IV) naloxone; 2) 0.8 mg intramuscular (IM) naloxone; 
3) 0.8 mg intranasal (IN) naloxone; 4) 2 mg intravenous naloxone; and 5) 2 mg intranasal naloxone. Naloxone 
400 μg/1 ml was used. Following these results, a covariate model was developed in which 1000 potential 
patients were simulated for each of the four arms of the study (0.8 mg and 2 mg IV, 0.8 mg IM, and 2 mg IN). 
The median time to peak naloxone concentration ranged from 12 minutes for intramuscular administration to 
between six and nine minutes for intranasal administration. The bioavailability for naloxone administered IN 
was 4% of that for IV and for IM bioavailability was 35% of that for IV. The simulated nomograms are illustrated 
below.
 
FIGURE 1. SIMULATED NALOXONE NOMOGRAMS FOR A) IV NALOXONE 0.4, 0.8, AND 2 MG; 
B) INTRAMUSCULAR DOSES 0.8, 1.6 AND 2.4 MG; AND C) INTRANASAL DOSES 2, 4, AND 
6 MG (C).(112)
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The authors state that the large volume of IN naloxone (up to 6 ml in each nostril in the 6 mg protocol) 
administered led to some being swallowed and subject to first pass metabolism, hence reducing the effective 
total dose (112).
A laboratory experiment examining IV administered naloxone’s ability to antagonise morpine (IV) in human 
subjects reported that naloxone exhibited clinical effect in 1–2 minutes and peak effect in 30 minutes. The 
duration of action of 0.2 mg of naloxone was between 1 and 1.5 hours; that of 0.4 mg was between 1.5 and 
2 hours, while 0.8 mg of naloxone resulted in an effect persisting beyond 4 hours (113).
Results of the literature search
Of the 5594 studies screened, two RCTs fulfilled eligibility criteria for key question 2 (66, 67). Both were field-
based RCTs conducted in Victoria, Australia where paramedics administered either IN or IM naloxone in the 
pre-hospital setting to suspected opioid overdose patients. No studies met the criteria for key question 3.
Characteristics of included studies
Kelly 2005 
Methods LOCATION
Rural and metropolitan Melbourne, Victoria, Australia
SETTING
Metropolitan Ambulance Service (MAS) and Rural Ambulance Victoria (RAV).
These services provide almost 100% of emergency ambulance response in Victoria.
DURATION OF RECRUITMENT
5 January 2002 – 19 December 2003
DURATION OF TRIAL
~24 months
OBJECTIVE
To compare IN naloxone (2 mg/2 ml) to IM naloxone for suspected OD.
Randomized controlled trial
Patients received either 2 mg IN naloxone (1 mg into each nostril) or 2 mg IM naloxone and supportive care for 
suspected opioid overdoses in the pre-hospital setting
IN was via mucosal atomization device (1 mg (1 ml) via each nostril)
Failure to respond at 8 minutes given rescue dose of 0.8 mg IM naloxone
Post OD care was recovery/discharge at scene or transport to hospital
Participants INCLUSION CRITERIA
Suspected opioid OD and unrousable
EXCLUSION CRITERIA
Nil stated
STUDY POPULATION
182 enrolled and randomized (IN 98, IM 84)
27 excluded
IN – 7 regained consciousness prior to treatment, 4 incomplete data, 3 technical problems
IM – 5 regained consciousness prior to treatment, 5 incomplete data
155 in final sample included for analysis (Intranasal 84, intramuscular 71)
Interventions INTERVENTION
Intranasal naloxone 2 mg via mucosal atomization device (1 mg / 1 ml via each nostril)
CONTROL
Intramuscular naloxone 2 mg
RESCUE NALOXONE (inadequate response at 8 minutes)
Intramuscular naloxone 0.8 mg
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Kelly 2005 
Outcomes PRIMARY
Response time, defined as the time to regain a respiratory rate greater than 10 per minute
SECONDARY
Proportion of patients with a respiratory rate greater than 10 per minute at 8 minutes
Proportion of patients with GCS score greater than 11 at 8 minutes
Proportion requiring rescue naloxone
Rate of adverse events
The proportion of the IN group for whom IN naloxone alone was sufficient treatment was also examined
Notes ETHICS
Royal Melbourne Hospital Human Research Ethics Committee
INFORMED CONSENT
Requirement for individual patient consent was waived (inclusion criteria was patient was unrousable)
Subjects were informed of their enrolment in the study by way of a study information brochure when they regained 
consciousness
FUNDING
William Buckland Foundation
Kerr 2009 
Methods LOCATION
Melbourne, Australia
SETTING
Six branches of Metropolitan Ambulance Service, which capture ~50% of all heroin OD in Melbourne
DURATION OF RECRUITMENT
1 August 2006 – 13 January 2008
DURATION OF TRIAL
16 months
OBJECTIVE
To compared concentrated IN naloxone (2 mg/ ml) to IM naloxone for suspected OD
Random allocation (opened envelope at scene) for paramedics (trained) to administer 2 mg IN or 2 mg IM naloxone 
and supportive care for suspected opioid overdoses in the pre-hospital setting
IN was via mucosal atomization device (1 mg/0.5 ml via each nostril)
Failure to respond at 10 minutes given rescue dose of 0.8 mg IM naloxone.
Post OD care was recovery/discharge at scene or transport to hospital
Participants INCLUSION CRITERIA
Suspected opioid OD (altered LOC, myosis, RR<10)+ unrouseable (GCS ≤ 12)
EXCLUSION CRITERIA
No major facial trauma, blocked nasal passages or epistaxis.
STUDY POPULATION
266 patients treated
178 randomized
6 excluded (3 become alert prior, 3 missing equipment) so 83 intranasal (IN) 89 intramuscular (IM)
172 included in the analysis (83 IN, 89 IM)
Interventions INTERVENTION
Intranasal naloxone 2 mg via mucosal atomization device (1 mg–0.5 ml via each nostril)
CONTROL
Intramuscular naloxone 2 mg
RESCUE NALOXONE (inadequate response at 10 minutes)
Intramuscular naloxone 2 mg
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Risk of bias
Random 
sequence 
generation 
(selection 
bias)
Allocation 
concealment 
(selection 
bias)
Blinding of 
participants 
and 
personnel 
(performance 
bias)
Blinding of 
outcome 
assessment 
(detection 
bias)
Incomplete 
outcome data 
(attrition bias)
Selective 
reporting 
(reporting 
bias) Other bias
Kelly 2005
Kerr 2009
Kerr 2009 
Outcomes PRIMARY
Proportion of patients with an adequate response within 10 minutes of naloxone administration defined as 
spontaneous respirations at a rate ≥ 10 per minute and/or GCS ≥ 13 (those having 2 doses of naloxone marked as 
inadequate, no matter the time frame)
SECONDARY
Time to adequate response
Hospitalization
Adverse event rate
Drug-related vomiting, nausea, seizure, sweating, tremor, acute pulmonary oedema, increased blood pressure, 
tremulousness, seizures, ventricular tachycardia and fibrillation, cardiac arrest, agitation and paraesthesia
Administration related nasal obstruction, nasal deformity
Study-related epistaxis, ruptured septum, spitting, coughing, leakage of solution from nasal passages
Requirement for ‘rescue’ naloxone due to inadequate primary response as judged by the treating paramedics.
Notes ETHICS
Melbourne Health Human Research Ethics Committee
INFORMED CONSENT
Requirement for individual patient consent was waived (inclusion criteria was patient was unrousable)
Subjects were informed of their participation by way of an information letter after regaining consciousness which 
allowed them to withdraw themselves from the study or seek further information
FUNDING
Drug Policy and Services, Department of Human Services, Melbourne, Victoria, Australia
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Forest plots by outcome
FIGURE 1 (ANALYSIS 1.1)
Forest plot of comparison 1: intranasal versus intramuscular naloxone; outcome 1.1: time to opioid overdose 
reversal
 
FIGURE 2 (ANALYSIS 1.2)
Forest plot of comparison 1: intranasal versus intramuscular naloxone; outcome 1.2: rescue naloxone given
 
FIGURE 3 (ANALYSIS 1.3)
Forest plot of comparison 1: intranasal versus intramuscular naloxone; outcome 1.3: adverse events (minor)
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FIGURE 4 (ANALYSIS 1.4)
Forest plot of comparison 1: intranasal versus intramuscular naloxone; outcome 1.4: opioid withdrawal reaction 
to naloxone (agitation/irritation/violence)
 
FIGURE 5 (ANALYSIS 1.5)
Forest plot of comparison 1: intranasal versus intramuscular naloxone; outcome 1.5: adverse events (major)
 
FIGURE 6 (ANALYSIS 1.6)
Forest plot of comparison 1: intranasal versus intramuscular naloxone; outcome 1.7: hospitalisation
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SUMMARY OF FINDINGS TABLE – KEY QUESTION 2
Intranasal compared to intramuscular administration of naloxone for opioid overdose
Patient or population: patients with opioid overdose
Settings: pre-hospital setting
Intervention: intranasal
Comparison: intramuscular
Outcomes
Illustrative comparative risks* (95% CI)
Relative 
effect
(95% CI)
No. of 
participants
(studies)
Quality 
of the 
evidence
(GRADE) Comments
Assumed risk Corresponding risk
Intramuscular Intranasal
Mortality See comment See comment Not 
estimable
— See 
comment
Not reported
Ease of 
administration1
See comment See comment Not 
estimable
— See 
comment
Not reported
Time to 
administration
See comment See comment Not 
estimable
0 
(0)
See 
comment
Not reported
Overdose 
complication
Adverse event 
(major)
6 per 1000 2 per 1000
(0 to 54)
RR 0.36 
(0.01 to 8.65)
327
(2 studies)
⊕2,3,4,5
VERY LOW
Overdose morbidity 794 per 1000 675 per 1000
(564 to 818)
RR 0.85 
(0.71 to 1.03)
327
(2 studies)
⊕⊕2,6,7
LOW
Opioid withdrawal 
reaction to 
naloxone
Agitation/irritation/
violence
100 per 1000 42 per 1000
(10 to 165)
RR 0.42 
(0.1 to 1.65)
327
(2 studies)
⊕2,8,9
VERY LOW
Time to opioid 
overdose reversal
Mean response 
time (mins)
The mean 
time to opioid 
overdose 
reversal 
in the 
intervention 
groups was
1.05 higher
(0.81 lower to 
2.91 higher)10
327
(2 studies)
⊕⊕2,6,11
LOW
Blood borne virus 
transmission
Not reported
Referral to 
treatment post 
overdose
Not reported
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Outcomes
Illustrative comparative risks* (95% CI)
Relative 
effect
(95% CI)
No. of 
participants
(studies)
Quality 
of the 
evidence
(GRADE) Comments
Assumed risk Corresponding risk
Intramuscular Intranasal
Rescue naloxone 
given
81 per 1000 213 per 1000
(119 to 382)
RR 2.62 
(1.46 to 4.7)
327
(2 studies)
⊕⊕2,12,13
LOW
* The basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95% confidence interval) is based on the assumed risk 
in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval. RR: Risk ratio.
GRADE working group grades of evidence
 High quality: Further research is very unlikely to change our confidence in the estimate of effect. 
 Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
 Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
 Very low quality: We are very uncertain about the estimate.
1 Neither of the trials reported this specifically. In Kelly 2005, 3 technical problems with Intramuscular were noted, not clearly associated with ease of administration.
2 Risk of bias: rated as serious. Although the studies were conducted well, lack of blinding may have resulted in performance bias and possible detection bias. 
3 Inconsistency: result comes from a single study (seizure in IM arm of Kerr 2009)
4 Indirectness: not downgraded. The two trials measured major adverse events which may or may not be related to overdose or naloxone administration.
5 Imprecision: rated as very serious. Only one event with a very wide confidence interval.
6 Inconsistency: not downgraded (note I2 = 49%). This may be driven by the difference in time measurement of adequate response (Kelly – 8 vs. Kerr – 10 mins) and 
the magnitude of outcome parameters ( Kelly – GCS > 11, RR > 10, Kerr – GCS ≥ 13, RR ≥ 10) 
7 Indirectness: marked as serious. Adequate response (as measured by RR or GCS at 8–10 minutes) is a proxy measure for overdose morbidity
8 Inconsistency: rated as serious. Measured as agitation/irritability in Kelly; measured as agitation/violence in Kerr. Unlikely to explain heterogeneity
9 Imprecision: rated as serious. Low event rate, wide confidence intervals.
10 Complete aggregated (Kelly) or disaggregated (Kerr) data not available. Included data in Kerr (GCS/RR), Kelly (RR only).
11 Imprecision: rated as serious. The confidence interval crosses the line of no effect and appreciable harm.
12 Inconsistency: not downgraded. While in Kelly 2005 rescue naloxone was given at 8 minutes and in Kerr 2009 at 10 minutes, this was no sufficient to justify 
downgrading (I2 = 5%) 
13 Indirectness: rated as serious. Administration of ‘rescue’ naloxone is a proxy measure for time to reversal as it indicates a delayed response.
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Evidence to recommendation framework
Summary of evidence
Meta-analysis of the two eligible RCTs found no difference between the administration of intranasal naloxone 
(initial dose 2 mg) vs. intramuscular naloxone (initial dose 2 mg) for opioid overdose. There was no difference in 
the rates of overdose complications (relative risk (RR) 0.36 [0.01 to 8.65]), overdose morbidity (RR 0.85 [0.71 to 
1.03]), opioid withdrawal reaction to naloxone (RR 0.42 [0.1 to 1.65]) or time to opioid reversal (mean difference 
(MD) 1.05 higher [0.81 lower to 2.91 higher]). There were no deaths in either study. Ease of administration 
was not estimable.
There were no studies examining IV administration compared to IN or IM naloxone administration in the pre-
hospital setting. 
There were no studies comparing different doses or dosing regimens of naloxone (such as titration versus 
single dose) in the pre-hospital setting. 
Benefits versus harms
Dose and concentration
An RCT conducted in 2009 in Victoria, Australia, which included 172 patients treated for suspected opiate 
overdose in the pre-hospital setting (median age 29, 74% male) (67) used 2 mg/5 ml IM and 2 mg/1 ml IN 
naloxone. In an earlier study conducted in 2005 in Victoria, another RCT of 155 patients suspected opiate 
overdose and attended by paramedics in the pre-hospital setting, the naloxone dose was the same (2 mg), 
but the concentration of the IN differed (2 mg/2 ml) (66). In the 2009 study, comparing IN and IM routes, 
using the higher concentration of IN naloxone, there was no significant difference between response times 
(8 min vs. 7.9 min) or rate of response at 10 mins (72.3% vs. 77.5%). In the 2005 study, which used a lower 
concentration of IN naloxone, time to respirations (>10/min) was faster in IM (6 min[5–7]) vs. IN (8min[7–8]) 
and the IM group was also more likely to have spontaneous respirations within 8 minutes (82% vs. 63% (p 
=0.0163 OR 2.6 [1.2–5.5]). This may indicate that the use of a more concentrated IN naloxone formulation 
results in an improved clinical response.
Route of administration
Intramuscular absorption is relatively rapid and comparable to IV in clinical effectiveness (81). In head-to-head 
comparisons, while IM naloxone may result in a more rapid clinical response, both are equally as effective with 
no additional need for naloxone in the IN group (66, 67).
An RCT in Victoria, Australia included 172 patients treated for suspected opiate overdose in the pre-hospital 
setting (median age 29, 74% male) (67). Subjects were administered 2 mg/5 ml naloxone by IM or IN (2 mg/
ml, 0.5 ml/nostril). Comparing IN and IM routes, there was no significant difference between response time 
(8 min vs. 7.9 min) or rate of response at 10 mins (72.3% vs. 77.5%). Supplementary oxygen was more often 
administered in the IN group (18.1% vs. 4.5%). The odds of providing rescue naloxone for inadequate response 
were OR 4.8 (p<0.01) comparing IN to IM. One major adverse event (seizure) was reported. There were no 
differences in adverse events. Agitation or withdrawal occurred in < 10% respectively in both groups.
In a second RCT in Victoria, Australia, of 155 patients suspected opiate overdoses attended by paramedics 
in the pre-hospital setting (median age 28–30 years, 70%–73% male), 71 individuals were treated with IM 
naloxone (2 mg/5 ml) and 84 with IN naloxone (2 mg/5 ml) (66). Clinical response (time to respirations > 10/
min) was faster in IM (6 min [5-7]) vs. IN (8min [7-8]).The IM group was also more likely to have spontaneous 
respirations within 8 minutes (82% vs. 63% (p =0.0163 OR 2.6[1.2-5.5]). There was no difference in the time 
to GCS >11 or having a GCS < 11 at 8 minutes or the proportion requiring rescue naloxone. 
In the meta-analysis combining the two studies, there were no statistically significant differences between IN 
and IM routes of administration. 
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Other evidence
In a classroom based RCT in Ireland, 18 advanced paramedic trainees were randomized to IN or IV naloxone 
administration for a simulated suspected opioid overdose on a mannequin. The mean time taken for the IN 
and IV group was 87.1 seconds and 178.2 seconds respectively. The difference in mean time taken was 
91.1 seconds (95%CI 55.2–126.9 seconds, p < 0.0001)(120).
In a study comparing 1 mg naloxone IN (per 0.4 ml) to IV and IM routes in 17 opioid dependent individuals, 
no significant differences between any of the groups were found regarding blood pressure and heart rate 
changes. The authors concluded that IN administration was comparable to IV in terms of the onset of clinical 
effect (withdrawal symptoms), while IM onset was delayed compared to IV (114).
A study of 2 mg IN naloxone (1 mg/ ml each nostril) in 30 pre-hospital patients in Utah reported a mean time to 
clinical response of 3.4 minutes in those who responded. Of the naloxone responders, 11/12 (91%) responded 
to IN naloxone alone, with 1 requiring an IV supplemental dose (115).
A retrospective review of EMS records compared IN to IV naloxone in California. There was no difference in the 
rate of clinical response between the IN and IV groups, although the time to clinical response was delayed in 
the IN versus IV group (12.9 versus 8.1 minutes, p = 0.02). Mean time from patient contact to clinical response 
was not significantly different between the IV and IN groups, suggesting that although clinical response was 
delayed for the IN route to IV, this was compensated by the delay in achieving IV access (116).
A retrospective review of patients who were administered IN or IV naloxone by paramedics in the pre-hospital 
setting for suspected opioid overdose in New Jersey identified 93 pre-arrest suspected opioid overdose patients, 
including 55 given IV naloxone and 38 given IN naloxone. Initial IV dose was between 0.4 and 2.0 mg, and 
initial IN dose was 2 mg (1mg each nostril) at the discretion of the paramedics. There was no difference in the 
respiratory rate or GCS change between IV and IN (117). The mean total dose for IN (1.95 mg) was higher than 
IV (1.71 mg) (p = 0.01), though the median dose for both groups was 2 mg. The median final RR was higher 
for the IV group than the IN group (18 versus 16; p = .001). The median final GCS score was also higher in the 
IV group than the IN group (15 versus 12; p = .01). Re-dosing was more common in the IN group (42%) than 
in the IV group (20%) though the decision to re-dose was at the discretion of the paramedic.
A number of observational studies on provision of IN naloxone for peer administration (following training) in 
the treatment of suspected opioid overdose reported rates of successful reversal close to 100% (48, 56, 118) 
with no serious problems in administration and no adverse events.
Harms
Use of a higher dose carries a greater risk of inducing an acute withdrawal syndrome. The RCT of 172 patients 
in Victoria, Australia, comparing IN and IM naloxone for pre-hospital administration found both well tolerated 
with no differences observed in agitation and/or violence (IN: 6.0%, IM: 7.9%), nausea and/or vomiting (IN: 
8.4%, IM: 7.9%) or headache (IN: 4.8%, IM: 3.3%) after naloxone treatment (67).
In the RCT of 155 patients in Victoria, Australia, comparing IN and IM naloxone for pre-hospital administration, 
there was no difference in adverse events between the two groups, although agitation/irritation was higher in 
the IM group (13% vs. 2%, p = 0.03) (66).  
A study in Boston evaluating an intranasal naloxone training and distribution programme of 385 enrolees 
reported 74 successful reversals, including four individuals not enrolled in the programme. However during 
four overdoses, the bystanders could not connect the mucosal-atomization device to the syringe, although 
each nonetheless resulted in successful reversal (56).
Intranasal preparations do not require a needle and therefore eliminate the risk of needlestick injury. There were 
no reports of injection-related adverse events to either the person with the overdose or the lay first responder 
in the evaluations of lay first responder naloxone programmes.  
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Higher-dose approaches may result in opioid withdrawal and, rarely, opioid-withdrawal- related adverse events. 
Lower-dose approaches may result in an increased risk of re-overdose when naloxone levels reduce. 
Values and preferences
A study on naloxone distribution and administration by peers in Australia found that 74% of interviewees 
preferred using the intranasal route of administration (68).
In a classroom-based RCT in Ireland, 18 advanced paramedic trainees were randomized to IN or IV naloxone 
administration for a simulated suspected opioid overdose on a mannequin. The IN route was reported as easier 
and safer to use than the IV route in 89% of advanced paramedic trainees (120). 
Naloxone 2 mg/2 ml IN administration provoked withdrawal symptoms in only 2/74 reversals (56).
Resource use
There is minimal difference in cost between intranasal and intramuscular formulations.
Feasibility
Intranasal naloxone may also be used on first patient contact while IV access is obtained for additional IV 
naloxone if necessary to optimise time to clinical response in the case of delayed IV access (119).
IV administration is essentially limited to trained health professionals.
Both intranasal and intramuscular administration of naloxone by laypersons is feasible.
Intranasal use of naloxone is an improvised “off-label” method of administration which has not passed through 
regulatory procedures.
DECISION TABLE: RECOMMENDATION 2
Judgements to inform the decision on the strength of the recommendation
For each of the above recommendations, the following were considered:
Factor GDG response
Is there high or moderate-quality evidence?
The higher the quality of evidence, the more likely is a strong recommendation.  
No
Is there certainty about the balance of benefits versus harms and burdens? 
In case of positive recommendations (a recommendation to do something), do the benefits 
outweigh harms? 
In case of negative recommendations (a recommendation not to do something), do the harms 
outweigh benefits?
Yes
Are the expected values and preferences clearly in favour of the recommendation? Yes
Is there certainty about the balance between benefits and resources being consumed?
In case of positive recommendations (recommending to do something) is there certainty that the 
benefits are worth the costs of the resources being consumed? 
In case of negative recommendations (recommending not to do something) is there certainty that 
the costs of the resources being consumed outweigh any benefit gained?
No
Strength of recommendation: the GDG decided to set the strength of the recommendation as ‘Conditional’.
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ANNEX 4  
KEY QUESTION 4 – EVIDENCE PROFILE AND 
DECISION TABLE
Key question 4
Should the resuscitation response to suspected opioid overdose, including by 
layperson bystanders, be based on standard CPR or chest compression only 
CPR? 
PICO formulation of key question for evidence synthesis
Population:  People with opioid overdose
Intervention:  Standard CPR based on the “ABC” approach (attending to airway, breathing, and circulation)
Comparison:  Resuscitation based on COCPR
Outcomes:  (see below)
OUTCOMES SELECTED AND RANKED BY GDG FOR KEY QUESTION 4
Outcome Importance
Overdose mortality Critical
Overdose complication (such as aspiration) Critical
Overdose morbidity (prolonged adverse outcome of opioid overdose) Critical
Opioid withdrawal reaction to naloxone Important
Adverse effect of resuscitation Important
Psychosocial intervention / referral to treatment post overdose Important
Background
Death from opioid overdose occurs as a result of cardiac arrest secondary to progressive respiratory failure and 
metabolic disturbances. Cardiac arrest is a late complication and associated with poorer outcomes as cerebral 
perfusion ceases at this point. 
The most recent International Consensus on Cardiopulmonary Resuscitation Guidelines, the European 
Resuscitation Council Guidelines and the American Heart Association Guidelines recommend the commencement 
of airway maintenance and assisted ventilation resuscitation efforts prior to the administration of naloxone for 
individuals with known or suspected opioid toxicity in respiratory depression but not in cardiac arrest (63–65). 
There have been two key changes to international cardiopulmonary resuscitation (CPR) guidance over the 
last 10 years. The first was the shift from a 15:2 to a 30:2 compression-ventilation ratio for lone rescuers 
making quality chest compression the main focus of the resuscitation effort. The second, in 2010, was a 
recommendation to shift to COCPR for layperson bystanders (63, 65).
Early resuscitation (e.g. CPR) of cardiac arrest (i.e. prior to pulseless electrical activity or asystole) is associated 
with improved outcomes (121) and may explain differences in survival between in-hospital and out-of-hospital 
cardiac arrests (122), as well as survival differences between adult and paediatric arrest (123).
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Given the importance of ventilation over cardiac output in most opioid overdoses, and the possibility of rib and 
sternal fractures with external cardiac massage, there may be a case for separate resuscitation guidelines in 
suspected opioid overdose compared to suspected cardiac arrest.
Evidence to recommendation framework
Summary of evidence
Of the 5594 studies screened, no studies fulfilled the eligibility criteria set.
There were no studies comparing one method of resuscitation with another in suspected opioid overdose.
A meta-analysis of RCTs and prospective cohort studies that compared standard CPR to COCPR for out-of-
hospital cardiac arrest was excluded as it did not specify people with suspected opioid overdose as a sub-
population.
Balance of benefits versus risks and harms
Benefits of standard CPR versus COCPR
In the context of opioid overdose, respiratory depression is the primary issue. 
A study in Melbourne of bystander-administered CPR for heroin overdose found the provision of CPR was 
associated with a lower rate of hospitalisation (13.9% vs. 17.7% p <0.05) compared with no CPR provision (70).
A study of 24 PWID provided with training in naloxone and CPR in San Francisco, found that during the six-
month follow-up period, 20 overdoses were witnessed by participants who provided CPR in 80% of events (58).
For individuals with respiratory depression who are pre-cardiac arrest, COCPR may result in unnecessary trauma, 
such as fractured ribs. A 2004 non-systematic review of skeletal injuries from CPR reported the incidence of 
rib fractures varied from 12.9% to 96.6% while for sternal fractures it was 1.3%–43.3% (76). The incidence of 
fractured ribs may be lower in younger populations such as children (76). 
In a US study of 7652 patients with out-of-hospital cardiac arrest examining bystanders’ response, where 
COCPR was performed on non-cardiac arrest victims (including overdose), there appears to be no negative 
impact on survival compared to no CPR (126). In contrast, a large Japanese study (n = 43 246) on COCPR and 
CPR for out-of-hospital cardiac arrest, found ventilation-based CPR associated with improved neurological 
outcomes in non-cardiac-origin cardiac arrests compared to COCPR. There was no difference in survival (75).
Harms (i.e. arguments for a COCPR based approach)
Most studies report that any CPR is better than no CPR. It is likely that COCPR will be used more often than 
ventilation/compression CPR. Early CPR (including chest compressions) is associated with better outcomes. 
Initiating rescue breathing only may delay the commencement of chest compressions. The benefit of chest 
compressions on ventilation is unclear. The prescribed benefit of COCPR is that it is simpler and therefore 
more likely to be performed correctly. 
In cardiac arrest, a meta-analysis of RCTs (there were three included RCT studies) found chest-compression-
only CPR (COCPR) to be associated with increased survival compared with standard CPR (RR 1.22 [1.01–1.46]) 
(71). In all three included RCTs, randomization occurred at the level of the dispatcher instructing the bystander 
(72–74). The secondary analysis of observational cohort studies found no difference between COCPR and CPR.
A retrospective cohort (chart review) in New Jersey of out-of-hospital cardiac-arrest patients during resuscitation 
using paramedic-initiated and medically-directed advanced life support (ALS) algorithms compared cardiac 
rhythms immediately before and after naloxone administration in 42 patients (125). Of these patients, 42% (n=15) 
demonstrated some change in their cardiac rhythm. Notably, 19% of all recipients demonstrated changes in cardiac 
rhythm immediately following naloxone but prior to additional ALS interventions. In addition, 20% of responders 
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(8% of all subjects) had a post-intervention rhythm sustainable with life. Examples of ECG changes were 
asystole or pulseless electrical activity (supraventricular tachycardia, ventricular tachycardia or ventricular 
fibrillation). All 21 non-responders died either in the pre-hospital setting or on arrival at ED. There were 4/15 
responders to naloxone that survived to admission, one survival to discharge from hospital. The authors 
recommend naloxone use in cardiac arrest at any suspicion of opioid over dosage. 
There is a theoretical risk of disease transmission with “mouth-to-mouth” assisted breathing, although it is 
not easily quantified.
Values and preferences
A study in Melbourne of bystander-administered CPR for heroin overdose found CPR was administered in only 
9.4% (579/5594 events) of ambulance attendances to heroin overdose (70).
A study in San Francisco of bystander responses to overdose as part of a pilot naloxone-distribution programme 
reported naloxone administration in 89% of overdose events, with rescue breathing given in 50%. Emergency 
services were only given in 29% of overdose events (57).
Key concerns about performing CPR (including mouth-to-mouth ventilation) include infectious-disease risk and 
lack of confidence in their ability to perform CPR correctly (127–129). Assisted ventilation (e.g. mouth-to-mouth) 
may potentially be less acceptable in circumstance where the victim is unknown or in certain cultures (129). 
The use of COCPR removes these issues.
A prospective cohort of bystanders in the USA who called an ambulance for cardiac arrest (of any cause, not 
necessarily related to overdose) reported that individuals with CPR training within five years were more likely 
to provide CPR than non-trained individuals (OR 4.5, [CI95 2.8–7.3]). Common reasons that the CPR-trained 
bystanders cited for not performing CPR were:
 o 37.5% stated that they panicked
 o 9.1% perceived that they would not be able to do CPR correctly
 o 1.1% thought that they would hurt the patient.
Only 1.1% objected to performing mouth-to-mouth resuscitation (130). Individuals may be more likely to perform 
CPR on victims they know (131).
Resource use
Training is required for bystanders to correctly implement CPR. COCPR may be associated with reduced training 
time and equipment.
Both forms of CPR require few resources. Assisted breathing may require a device to avoid skin to skin contact, 
such as a sheet of plastic with a hole in it or a mask. 
Feasibility
Both forms of CPR were feasible in all studies, notwithstanding cultural issues with mouth-to-mouth 
resuscitation.
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DECISION TABLE: RECOMMENDATION 3
Judgements to inform the decision on the strength of the recommendation
For each of the above recommendations, the following were considered:
Factor GDG response
Is there high or moderate-quality evidence?
The higher the quality of evidence, the more likely is a strong recommendation.  
No
Is there certainty about the balance of benefits versus harms and burdens? 
In case of positive recommendations (a recommendation to do something), do the benefits 
outweigh harms? 
In case of negative recommendations (a recommendation not to do something), do the harms 
outweigh benefits?
Yes
Are the expected values and preferences clearly in favour of the recommendation? 
What is most clear is the values and preferences e.g. people not being comfortable about mouth-
to-mouth should be remembered.
Yes
Is there certainty about the balance between benefits and resources being consumed?
In case of positive recommendations (recommending to do something) is there certainty that the 
benefits are worth the costs of the resources being consumed? 
In case of negative recommendations (recommending not to do something) is there certainty that 
the costs of the resources being consumed outweigh any benefit gained?
Yes
Strength of recommendation: the GDG decided to set the strength of the recommendation as ‘Strong’.
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ANNEX 5  
KEY QUESTION 5 – EVIDENCE PROFILE AND 
DECISION TABLE
Key question 5
What should be the response to opioid overdose after the administration of 
naloxone and successful reversal of opioid overdose in the community, including 
by lay first responders? 
PICO formulation of key question for evidence synthesis
Population:  People with opioid overdose managed in the community setting
Intervention:  Observation (for example by transfer to hospital, or staying with the person)
Comparison:  No observation (lay first responders) or discharge on-scene (by medical staff)
Outcomes:  (see below)
OUTCOMES SELECTED AND RANKED BY GDG FOR KEY QUESTION 5
Outcome Importance
Overdose mortality Critical
Overdose complication (such as aspiration) Critical
Overdose morbidity (prolonged adverse outcome of opioid overdose) Critical
Aggression directed towards the person encouraging observation by the overdose victim Critical
Second overdose event within 24 hrs Critical
Opioid withdrawal reaction to naloxone Important
Psychosocial intervention / referral to treatment post overdose Important
Background
Post-resuscitation care refers to the time period immediately following the restoration of spontaneous respiration 
and circulation following an overdose.
The half-life of naloxone is shorter than that of many opioids. Consequently, post resuscitation care in long-
acting overdoses may be prolonged. Additionally, while there is crossover between heroin users and users of 
prescribed, long-acting opioids, epidemiologically these patient populations do differ. 
Evidence to recommendation framework
Summary of evidence
Of the 5594 studies screened, no studies fulfilled eligibility criteria.
Balance of benefits versus risks and harms
A prospective-cohort study designed to determine the clinical characteristics of patients with presumed opioid 
overdose who could be safely discharged from the ED one hour following the use of naloxone in Vancouver 
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TABLE 7. OPIOID HALF-LIFE COMPARATIVE TABLE1,2
Drug Plasma half-life (hours)
Short half-life opioids
Heroin3 3–5 min
Morphine 2–3.5
Morphine-6-glucoronide4 2
Hydromorphone 2–3
Oxycodone 2–3
Fentanyl 3–4
Codeine 3
Meperidine/pethidine 3–4
Buprenorphine 3–305
Long half-life opioids
Methadone 24
Propoxyphene 12
Norpropoxyphene4 30–40
Normeperidine4 14–21
Opioid antagonists
Naloxone 1–1.5
Nalmefene 8–9 
Naltrexone/6-ß-naltrexol4 4/13
1 Active metabolites may prolong pharmacological effects beyond the half-life listed 
here.
2 Sustained release preparations alter absorption kinetics to delay time to peak plasma 
concentration thereby extending clinical effect.
3 Has active metabolites responsible for perceived longer duration of action.
4 Active metabolites of other opioids.
5 Depending on the dose; low doses used for short term analgaesia are typically  
0.2–0.3 mg whereas high doses used for opioid dependence are 2–32 mg.
Source: Adapted from (133)
included 573 patients in the analysis. A decision-tree rule was developed which predicted safe discharge with a 
sensitivity of 99% and specificity of 40% (82). The authors stated that patients with presumed opioid overdose 
can be safely discharged one hour after naloxone administration if they: 
 o can mobilize as usual
 o have oxygen saturation > 92%
 o have a respiratory rate between 10–20
 o have a temperature between 35.0–37.5C 
 o have a heart rate  of 50–100 bpm
 o have a GCS of 15.
Almost all patients in the following several studies that were followed in the analyses after ‘discharge-on-scene’ 
refused transportation.
A prospective study linking a pre-hospital emergency care and the forensic examiner’s database in Copenhagen 
over 10 years identified 3245 individuals treated for opioid overdose, 2241 of whom were released on-scene. 
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Rebound opioid toxicity was identified in three of the 14 deaths recorded within 48 hours of receiving naloxone, 
which equates to 0.13% of overdoses (77).
There were a number of retrospective studies identified which used cross-linkage of EMS and medical examiner 
databases to investigate post naloxone for heroin overdose-related deaths.
A retrospective review cross-linking out-of-hospital naloxone administration for opioid overdose and medical 
examiner databases for opioids as a cause of death over a five-year period in San Diego identified 998 out-of-
hospital patients who received naloxone and refused further treatment and 601 medical-examiner cases of 
opioid overdose deaths. There were no cases in which a patient was treated by paramedics with naloxone 
within the 12 hours previous to being found dead of an opioid overdose. Two doses of 2 mg naloxone (IV or 
IM) were administered in 71.5% of cases, three doses in 2.4% (80).
A retrospective review of the management of opioid overdose by emergency medical services in San Francisco 
reported 575 of 609 (94%) of individuals identified with opioid overdose and having a measurable blood pressure 
responded to naloxone. Ambulance transfer to hospital was made for 444 (74%) of individuals, and 97% of 
these were discharged without further intervention. The remaining 3% were admitted for various complications 
including non-cardiogenic pulmonary oedema, infection and overdoses unresponsive to naloxone (presumed 
polysubstance overdose) (81). Less than 2 mg of naloxone was administered in only 7% of cases.
A retrospective study of presumed heroin overdoses treated by EMS cross-linked to a cardiac arrest database 
and medical examiner database in Helsinki identified 145 patients with presumed heroin overdose. There were 
84 patients who were not transported to hospital. Of these, 71 had received pre-hospital naloxone (median dose 
0.4 mg, 75% < 0.6 mg), eight were given ventilation alone and five recovered spontaneously. All 84 patients 
had GCS 14 or 15 and showed no signs of hypoventilation. Of the 71 patients who had received naloxone, 
there were no deaths reported within 12 hours of administration (78).
A retrospective review of EMS and medical examiner databases in San Antonio identified 592 patients treated 
for presumed opioid overdose who refused further care or transportation. There were no deaths recorded 
within 48 hours of naloxone administration in this group. There were nine deaths recorded within 30 days of 
naloxone administration, but the shortest time between naloxone and death was four days (79).
Transfer to hospital may be an opportunity to link with a drug treatment or other health service. 
Risks (no observation)
The risk of rebound opioid toxicity following administration of naloxone resulting in death within 48 hours 
appears to be 0%–0.13% according to several prospective and retrospective data-linkage analyses in high 
income settings (77–79, 81, 82, 134).
The risk of non-cardiogenic pulmonary oedema is low. An in-hospital case series of 1278 individuals identified 
27 patients (2.1%) with non-cardiogenic pulmonary oedema from heroin overdose. Only patients who presented 
to the hospital were included in the case series (135).
Values and preferences
People who inject drugs may be reluctant to transfer to hospital following an opioid overdose for post-
resuscitation care.
Post-naloxone, an individual may have symptoms of acute opioid withdrawal and may be less likely to cooperate 
with emergency medical services.
Where people who use drugs are subject to stigma and discrimination, individuals having an overdose may be 
reluctant to attend a health service for post-resuscitation care.
In resource-limited settings, hospital-based post-resuscitation care may be limited.
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Where universal health care is not available, costs to the consumer may be associated with post-resuscitation 
care, influencing desire to attend such services.
Resource use
Discharge on-scene post-naloxone may be less resource intense for emergency medical services and health 
facilities.
Health facility-based post-resuscitation care is associated with resource availability and service use. The cost 
of post-resuscitation care to the consumer varies by jurisdiction. 
The cost of providing post-resuscitation care in a health facility varies by country and region. Minimal needs 
might include:
 o ability to transfer the patient to a health facility;
 o ability to observe and monitor the patient at the health facility in case of opioid toxicity reoccurrence;
 o ability to treat reoccurrence of opioid toxicity with naloxone, ventilation and oxygen as necessary.
Lay first responders may be happy to stay with the opioid-overdose person until the period of re-overdose risk 
is over.
Feasibility
Provision of post-resuscitation care depends on the availability of medical services.
Lay first responders (and health professionals) may not be able to tell the difference between short and long 
half-life opioids.
DECISION TABLE: RECOMMENDATION 4
Judgements to inform the decision on the strength of the recommendation
For each of the above recommendations, the following were considered:
Factor GDG response
Is there high or moderate-quality evidence?
The higher the quality of evidence, the more likely is a strong recommendation.  
No
Is there certainty about the balance of benefits versus harms and burdens? 
In case of positive recommendations (a recommendation to do something), do the benefits 
outweigh harms? 
In case of negative recommendations (a recommendation not to do something), do the harms 
outweigh benefits?
Yes
Are the expected values and preferences clearly in favour of the recommendation? Yes
Is there certainty about the balance between benefits and resources being consumed?
In case of positive recommendations (recommending to do something) is there certainty that the 
benefits are worth the costs of the resources being consumed? 
In case of negative recommendations (recommending not to do something) is there certainty that 
the costs of the resources being consumed outweigh any benefit gained?
Yes
Strength of recommendation: the GDG decided to set the strength of the recommendation as ‘Strong’.
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ANNEX 6  
VALUES-AND-PREFERENCES SURVEY AND KEY-
INFORMANT INTERVIEWS
Online survey
In addition to the in-depth interviews below, an online values-and-preferences survey was conducted between 
4 February and 20 February. The method was a snowball technique where the initial recipients of the invitation 
were the meeting participants, WHO collaborating centres and regional offices. There were 661 responses from 
45 countries. The survey and its results are available at https://www.surveymonkey.net/results/SM-W7TT3YT/
summary.
In-depth interviews
Summary
A values-and-preferences study of people who inject drugs explored the experiences and views of 32 people 
around HIV prevention, HIV testing modalities, anti-retroviral treatment (ART) for treatment and prevention 
of HIV, harm reduction and community distribution of naloxone. The study was conducted from January to 
March 2014 and included 25 members of the PWID community and seven experts or service providers who 
work closely with this community. Nineteen individuals participated in in-depth interviews, two participants 
responded by email, due to language restrictions, and 11 individuals participated in a group discussion of the 
same issues covered in the interviews. 
The main findings regarding PWID and community preferences on the pre-hospital management of opioid 
overdose are summarized in the box below.
The larger issues that influence the potential impact of harm-reduction interventions are poverty, 
homelessness, mental illness, social exclusion and joblessness. 
Community distribution of naloxone should be added to the list of harm-reduction interventions.
Naloxone is a cheap, safe, easy-to-use, life-saving drug. It should be available for community 
distribution to people who inject drugs, their peers and their families. 
Pre-loaded syringes or nasal spray are preferred.
The importance of rescue breathing must be emphasized along with distribution of naloxone.
1. Introduction 
One aspect of the WHO guidance-development process involves engaging with communities to understand 
their values and preferences regarding elements of potential recommendations that will have a direct impact 
on their lives. Their views and experience are considered along with systematically-reviewed evidence and 
expert opinion. In this way, guidance can be more responsive to the needs of individuals who are confronting 
the challenges being addressed by new recommendations and guidance.
This report summarizes the findings of a qualitative study that explored the perspectives and experiences of 
active drug injectors and former PWID regarding the out-of-hospital management of opioid overdose. 
The survey was part of a larger survey conducted to support the development of key population guidelines 
for HIV prevention and treatment. 
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2. Methods
An independent consultant conducted the study to ensure impartiality in the interviews and in the analysis 
of findings. Thirty-five prospective participants – members of the PWID community, experts, activists and 
service providers – were identified through international and regional networks and invited to participate in 
semi-structured, in-depth interviews regarding their personal experiences with and perspectives on:
 o HIV prevention strategies
 o HIV testing modalities
 o the use of antiretrovirals for prevention of HIV
 o the comprehensive harm-reduction package
 o community distribution of naloxone. 
Twenty-six people agreed to participate, and 19 people were actually able to participate in interviews, while 
two respondents provided written answers due to language constraints. In addition, 11 young injecting drug 
users (ages 16–25) participated in a group discussion of the interview topics led by one of the study participants 
who works with an organization serving the needs of young homeless people in San Francisco, USA. Those 
findings are also included in this report, comprising the views of 32 individuals (ages 16–57 years).
Two interview guides were developed in a consultative process with WHO and other experts in the field, one 
for PWID community members and one for experts and service providers who did not identify themselves 
as PWID. The different sets of questions reflect a distinction between the values and preferences of PWID 
community members – the primary focus of this study – and the views of those who work closely with the 
community but who may not have the same personal experience of the topics covered. Where views of the two 
groups differ, this is noted. Interviews were 1–1.5 hours in length, and they were recorded with participants’ 
permission. Recordings were used only by the interviewer to facilitate analysis and ensure accuracy of quotes. 
All participants gave their verbal consent to participate in the study. 
Due to the limited number of participants in this study, the content of interviews was not categorized as majority 
or minority positions. Findings were analysed by assessing the level of support for new interventions being 
proposed and highlighting areas where positive views were qualified by concerns around ethics, feasibility, 
acceptability or other issues. Unique views are also included in the report as they contribute important 
perspectives to the analysis of findings and should be noted in the guidance-development process. Findings 
are summarized in boxes at the opening of each topic section, and the narrative report reflects the analysis of 
findings as they emerged in interviews. Direct quotes are used to capture the detail and tone of participants’ 
contributions. However, quotes are not identified by gender or country in order to maintain the anonymity of 
respondents.  Some views are identified by region where conditions and experiences appear to be significantly 
different from other regions. In general, references are not made to individual countries unless in relation to 
specific data. 
3. Participant profiles
Africa Americas South-East Asia Europe
Eastern 
Mediterranean Western Pacific
Women 2 7 — 2 2 2
Men 2 8 3 4 — —
Note: Age range of participants is 16–57 years.
1 One service provider from Europe works in Africa; 2 PWID and 1 expert from Europe work with international networks; 1 expert from Western 
Pacific works with an international network; 11 adolescents and young people who inject drugs (in the USA) contributed views during a group 
discussion facilitated by a study participant. 
TABLE 1. PARTICIPANT PROFILES BY GENDER AND REGION1 
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Member of PWID 
community
Expert/activist/
service provider
Current injecting drug use 16 (5)
Former injecting drug use 9 2 (7)
Never used or no answer — 5
Note: Numbers in parentheses indicate current or former injecting drug users who identify as members of 
the PWID community as well as experts, activists or service providers for the community.
1 Two respondents who self-identified as former injectors reported that they are likely to use injecting drugs 
again in the future; their inputs reflect an ongoing concern about their own access to harm reduction 
services. 
TABLE 2. PARTICIPANT PROFILES BY SELF-IDENTIFICATION AND INJECTING DRUG USE1 
Contributors to this study live in urban areas. Eighteen people work in a wide range of settings: 
 o community-based services in capital cities and provincial towns; 
 o international, regional and national networks of PWID (or drug users more generally) based in urban areas 
in the North and South; 
 o street-based and mobile services in all regions.
Eleven participants in a group discussion are homeless young people who inject drugs and one participant, 
affiliated with a university, focuses primarily on research. None of the participants were service providers in 
public-health settings.
4. Study findings
4.1 Community distribution of naloxone
Key findings regarding community distribution of naloxone are highlighted in the box below.
1) Naloxone is a cheap, safe, easy-to-use, life-saving drug. It should be available for community 
distribution to people who inject drugs, their peers and their families. 
2) Community distribution of naloxone should be added as an element of the comprehensive 
harm-reduction package.
3) Pre-loaded syringes or nasal sprays are preferred.
4) The importance of rescue breathing must be emphasized along with distribution of naloxone.
“Naloxone saves lives.”
“We deserve to live, to be okay, to have more chances. We have lives of value, we are 
people, too.”
 
“People are dying every day [here]”. The quality of drugs is changing every day because 
heroin is often not available and so people have to take whatever they can find, and it’s 
very difficult to find the right doses, and so overdose happens all the time. Naloxone 
used to be more available with Global Fund money and it was so successful, and service 
providers distributed naloxone in the communities, and it helped a lot and saved a lot of 
lives. But the Global Fund has not been operating since 2013, now there is [not enough] 
naloxone.” 
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The discussions of community distribution of naloxone were brief and the views were clear. Thirty-one 
respondents (one is based in a country where injecting drug use is limited to stimulants, and naloxone was 
not discussed) expressed unqualified support for making naloxone widely available without prescription and 
without burdensome conditions. Three respondents acknowledged that overdose is not a significant problem 
in their settings, however they felt that naloxone should be available to every person who injects opiates. 
 
“Availability with prescription (as is the case in many countries) is not enough – it needs 
to be in the hands of peers, families etc., so that it is easily available.”
Many respondents feel that resistance to making naloxone more widely available to the PWID community 
and their families and friends can have a dramatic effect in terms of further marginalization of members of the 
community, reinforcing a sense of alienation from society, which only makes injecting drug users more reluctant 
to seek and use vital harm-reduction and other health services. In many countries, continued criminalization of 
PWID also deters peers from getting emergency assistance when someone has overdosed. 
“There’s something so symbolic about naloxone. It’s a life-saving intervention. If you say 
community distribution is not worth [doing], it’s a value judgment on our lives.” 
“What does that say about us if you’re willing to let us die when there’s such a preventative 
option in place? [Even if] you oppose harm reduction fundamentally, not being willing to 
save our lives feels so alien and says so much about what you think about us, and then 
that affects how we want to engage in services.”
In general, availability of naloxone is variable across regions. In Europe and North America, availability is 
becoming more widespread but there is not universal access, and it can still be difficult to access naloxone for 
peer distribution. In most countries where naloxone is legal and available for community use, there are usually 
conditions that require a prescription and training. In almost all of those cases, only a small amount is given to 
each person, generally a 2 ml vial, which may be sufficient for one or two doses, depending on the situation. 
Respondents who mentioned the doses all felt that it would be better to have larger quantities available for 
community distribution. 
Ideally, a sufficient and consistent supply of naloxone for peer workers to distribute along with basic training 
could create a cascade out to all members of the community. Training must continue to emphasize the 
importance of rescue breathing. One respondent worries that widespread availability of naloxone could 
overshadow the critical importance of this overdose management strategy. Another respondent feels that 
rescue breathing must be designated as preferable to chest compressions which are advised in her setting, 
but which result in additional trauma (e.g. cracked ribs).
In sub-Saharan Africa and South Asia, availability is much more limited. In most cases, only health professionals 
are allowed to administer it; in some cases, health providers themselves are not aware of it. In many Eastern 
Mediterranean countries, naloxone is available only at government health facilities, and only some first 
responders have access to it.  Administration of naloxone requires a doctor’s permission, which in turn triggers 
a report to the police. 
“Often people will be thrown on the street to die because they are afraid of trouble with 
the police.”
One respondent in sub-Saharan Africa raised the issue of health information systems as an issue to be addressed 
when advocating for naloxone.
“Current death registration masks the real extent of the problem; death caused by OD 
is called ‘pulmonary embolism’, so we don’t have the real numbers to use when we 
advocate for wider distribution of naloxone.”
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Arguments against community distribution of naloxone are considered to be baseless.
 “The main resistance is based on a belief that people will feel safer and engage in more 
high -risk behaviour and try to get as close to OD as possible, because we have naloxone  
sitting there. It’s a ridiculous argument. It’s true, for some users this is part of the game, 
getting as close as possible without overdosing. But if you know what it’s like to go over  
and then get brought out with naloxone, which is not a pleasant experience, then  actually 
getting your ‘stone’ right makes much more sense than being reckless, you can  enjoy 
it without being interrupted. The arguments against naloxone just don’t add up.  And 
there are complexities to the situation that don’t fit with this simplistic assumption  that 
people will act more recklessly (e.g. there may be other substances such as alcohol  that 
are changing the way the body is processing the drug, or a health condition that  makes 
the drug act differently).”
 “Dealing with overdose is scary. There are no downsides to having naloxone. We could 
be saving people’s lives! When you work with this community, you lose so many people.  
People’s lives could be saved so easily, it’s so easy to administer, it’s so logical. The reality 
is that people hate drug users... and some people feel it’s a waste of money if you’re 
using it for drug users.” 
When asked if there are any downsides to community distribution of naloxone, one respondent summed up 
the views of all participants —
“None. What kind of question is that?” 
5. Conclusion
There was very strong support from the study participants for the wider availability of naloxone for the 
management of opioid overdose. 
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An estimated 69 000 people die each 
year from opioid overdose, which is 
easily treatable with naloxone and basic 
resuscitation techniques, a treatment that 
is usually only available in ambulances and 
hospital settings. Most opioid overdoses 
are witnessed, often by someone known 
to the person who has overdosed, such 
as a friend, family member or professional 
whose work brings them into contact with 
people at risk of overdose. This guideline 
makes specific recommendations for 
health services to work with such lay 
persons who are likely to witness an opioid 
overdose, to enable them to treat opioid 
overdose in an emergency situation and 
prevent further opioid overdose deaths. 
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